リウマチ病セミナー　XIX

出版社： 永井書店
著者：
発行日： 2008-12-20
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784815918248
シリーズ： リウマチ病セミナー
電子書籍版： 2008-12-20 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,020 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,510 円(税込)

購入する

商品紹介

リウマチ学の進歩に沿った新しい知見や発見に関する論文、及びリウマチ病の臨床の現場に役立つ論文も多い。

目次

  • リウマチ病セミナー　XIX

    ―目次―

    炎症リウマチ
    　シェーングレン症候群とミクリッツ病
    　自律神経とRA
    　関節リウマチと煙草
    　爪の変化とリウマチ病
    　女性の痛風

    骨関節、脊椎、神経
    　骨粗鬆症性椎体骨折の治療
    　ゴルフとリウマチ症状
    　線維筋痛症のレゾンデートル
    　　―運動器疾患患者の全人的ケアへのいざない―
    　stiff-personn症候群
    　異所性骨化（heterotopic ossification）
    　脳脊髄液減少症

    検査法
    　骨質の評価
    　坑CCP抗体の臨床的意義
    　血沈の意義

    生物学的反応
    　糖鎖とリウマチ病
    　IL-17（Interleukin-17)
    　Osteocyte最近の知見
    　坑TNF-α療法による滑膜炎症と骨・軟骨破壊との乖離

    治療と副作用
    　CTLA4-lgキメラ（アバタセプト）の有効性
    　リウマチ患者に多い訴えとその対策
    　IL-1Ra(IL-1 receptor antagonist)
    　RA患者の履物
    　ステロイド療法2007
    　タクロリムス（プログラフ）の使い方
    　慢性疼痛（慢性痛症）の薬物治療
    　腰痛と腰椎牽引療法
    　新薬の臨床試験（Clinical Trial）に関する反省
    　　―内科医からみたリウマチ性疾患の診断・治療上の問題点―

    手術
    　関節リウマチ患者の前足部形成術

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

炎症リウマチ

P.8 掲載の参考文献
1) Mikulicz J. Uber eine eigenartige symmetrishe Erkrankung der Tranen und Mundspeicheldrusen. Beitr. z. Chir. Fesrschr. f, Theodor Billroth, Stuttgart, 1892: pp610-630.
 
2) Sjogren H. Zur Kenntnis der Keratoconjunctivitis Sicca. Acta Ophthalmol 1933; Suppl. II: 1-151.
 
3) Sjogren H A new conception of keratoconjunctivitis sicca 1943, Sydney, Australasian Medical Publishing Company (translated by Hamilton JB).
 
4) Morgan WS, Castleman B. A clinicopathologic study of"Mikulicz's disease". Amer J Pathol 1953; 29: 471-503.
 
5) 山中 学, 笠原 茂, 三田村忠行ら, 最近当科で経験したミクリッツ病の3例-シェーグレン症候群との異同についての文献的考察.関東リウマチ1995; 29: 185-194.
 
6) 山本元久, 鈴木知佐子, 苗代康可ら. ミクリッツ病における疾患独立性の意義-Revival of interests in Mikulicz's disease-. 日臨免誌2006: 29: 1-7.
 
7) Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344: 732-738.
PubMed
8) 日本膵臓学会: 日本膵臓学会自己免疫性膵炎診断基準2002年. 膵臓2002; 17: 585-587.
 
9) Tsubota K, Fujita H, Tsuzuka K, et al. Mikulicz's disease and Sjogren's syndrome. lnvest Ophthalmol Vis Sci 2000; 41: 1666-1673.
 
10) 山本元久, 鈴木知佐子, 苗代康可ら. Mikulicz病の臨床像および小唾液腺組織におけるアポトーシスの解析. 日臨免誌2002; 25: 416.
 
11) Spiegelberg HL. Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol 1974: 19: 259-294.
 
12) 正木康史, 管井 進, 下山久美子ら. 40例のAMOLPs (自己免疫性リンパ増殖性多臓器疾患) /Mikulicz病の検討. 第14回日本シェーグレン症候群研究会抄録集. 2005, p68-69.
 
13) 山本元久, 高橋裕樹,苗代康可ら. ミクリッツ病と全身性IgG4関連疾患. 日臨免誌2008; 31: 1-8.
 
P.16 掲載の参考文献
1) Barendregt PJ, van der Heijde GL, Breedveld FC, et al. Parasympathetic dysfunction in rheumatoid arthritis patients with ocular dryness. Ann Rheum Dis 1996; 55: 612-615.
PubMed
2) Rogers MP, Fozdar M. Psychoneuroimmunology of autoimmune disorders. Adv Neuroimmunol 1999; 6: 169-117.
 
3) Thompson M, Bywaters EGL. Unilateral arthritis following hemiplegia. Ann Rheum Dis 1962; 21: 370-377.
 
4) Hearn MA, Fireman BH. Stress management and mutual support groups in rheumatoid arthritis. Am J Med 1985; 78: 771-775.
 
5) 七川歡次. リウマチ診療の変遷.越智隆弘 (編集), 最新整形外科学大系, 関節リウマチと類縁疾患19. 東京, 中山書店, 2007: 2-9.
 
6) Kapkan R. Robinson C. Scavulli J et al. Propranolol and the Treatment of rheumatoid arthritis, arthritis and Rheumatism, 23. 2. 1980. 253-255.
 
7) Levine J, Fye K, Heller P, Basbaum A et al. Clinical Response to Regional Intravenous Guanethidine in Patients with Rheumatoid Arthritis. The Journal of Rheumatology 1986: 13: 6, 1040-1043.
PubMed
8) Marshall AT, Cisp AJ. Reflex sympathetic dystrophy. Rheumatology (Oxford) 2000; 39: 692-695.
 
9) 若杉文吉. 星状神経節ブロック療法. 1版. 東京, マキノ出版, 2005: 150-237.
 
10) 大槻 学, 村川雅洋. 内分泌への影響.小川節郎 (編集), 星状神経ブロックの生理的意義, 1版. 東京, 真興貿易 (株) 医書出版部, 2007: 44-56,
 
11) 岡田まゆみ, 久光正. 免疫系への作用. 小川節郎 (編集), 星状神経節ブロックの生理的意義, 1版. 東京, 真興貿易 (株) 医書出版部, 2007: 57-64.
 
12) Baum A, Grunberg. ストレスホルモンの測定. 小杉正太郎 (監訳), ストレス測定法, 1版. 東京, 川島書店, 1999: 251-274.
 
13) 岩永敏彦. ペプチド作動性神経. 自律神経の基礎と臨床, 後藤由夫・本郷道夫 (編集), 改訂3版. 大阪, 医薬ジャーナル2006: 61-65.
 
14) Pernow J, Lundberg JM, Kaijser L, Hjemdahl P et al. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol 1986; 6: 561-78.
PubMed
15) 岩瀬 敏 自律神経機能検査方概論. 平井俊策・板東武彦 (編集), 最新自律神経学, 1版. 東京, 新興医 学出版社, 2007: 173-189.
 
16) 間野忠明. マイクロニューログラフィ. 後藤由夫・本郷道夫 (編集), 自律神経の基礎と臨床, 改定3版. 大阪, 医薬ジャーナル2006: 99-106.
 
17) 向野和雄. 臓器機能に関連する自律神経系の生体基礎機能. 平井俊策・板東武彦 (編集), 最新自律神経学, 1版. 東京, 新興医学出版社, 2007: 109-172.
 
18) 早野順一郎. 心拍変動. 後藤由夫・本郷道夫 (編集), 自律神経の基礎と臨床, 改定3版. 大阪, 医薬 ジャーナル2006: 147-156.
 
19) Evrengul H, Dursunoglu D, Cobankara V. Heart rate variability in patients with rheumatoid arthritis. Rheumatol Int. 2004, 24: 198-202.
PubMed
20) Tanaka S, Ohnishi N, Tominaga Y. Histochemical demonstration of adrenergic nerve fibers and serotonin-containig mast cells of the knee joint synovial membrane in rats. Experimentia 1977; 33: 52-53.
 
21) Ohnishi N, Tanaka S, Ueo T at al. Fluorescence histochemical studies of adrenergic nerve fibers and serotonin containing mast cells of the knee joint synovial membrane in normal and experimantal arthritic rats. Intern Orthop 1978; 2: 15-16.
 
22) 田中清介, 上尾豊二, 大西紀夫ら. 関節炎の発症における交換神経の役割. リウマチ病V, 大阪, 永井書 店, 1979: 83-100.
 
23) 宗圓 聰, 田中清介, 山本 哲. 家兎滑膜におけるノルアドレナリン受容体. 整形外科 1984; 11: 312-313.
 
24) 宗圓 聰, 田中清介, 山本 哲. 慢性リウマチ患者における滑膜中ノルアドレナリン受容体. 炎症 1984; 4: 289-290.
 
25) 宗圓 聰, 田中清介, 喜多 寛. 実験的関節炎滑膜のノルアドレナリン受容体. 炎症 1983; 3: 473-474.
 
26) 田中清介. 関節炎におけるアドレナリン受容体. 臨床免疫 1985; 17: 809-812.
 
27) 宗圓 聰, 田中清介, 喜多 寛ら. 抗原惹起型関節炎におけるリンパ球中ノルアドレナリン受容体. 整形外科基礎科学 1985; 12: 27-29.
 
28) 宗圓 聰. 慢性関節リウマチおよび実験的関節炎におけるリンパ球, 滑膜のアドレナリン受容体. 近畿大医誌 1988: 13: 251-264.
 
29) Mapp PL, Kidd BL, Gibson SJ, et al. Substance P-, calcitonin gene-related peptide-and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis. Neuroscience 1990; 37: 143-153.
 
30) Schwab W, Bilgicyildirim A, Funk RH. Microtopography of the autonomic nerves in the rat knee: A fluorescence microscopic study. anat Rec 1997; 247: 109-118.
 
31) Baerwald CG, Laufenberg M, Specht T, et al. Imapaired sympathetic influence on the immune response in patients with rheumatoid arthritis due to lymphocyte subset-specific modulation of beta 2-adrenergic receptors. Br J Rheumatol 1997; 36: 1262-1269.
PubMed
32) Baerwald C, Burmester G, Krause A. Interactions of autonomic nervous, neuroendocrine, and immune systems in rheumatoid arthritis, Rheuma Dis Clin N Am 2000; 26: 841-856.
 
33) Davies AO, Lefkowitz RJ. In vitro desensitization of beta adrenergic receptors in human neutrophils. Attenuation by corticosteroids. J Clin Invest 1983; 71: 565-571,
PubMed
34) Izeboud CA, Mocking JA, Monshouwer M, et al. Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J Recept Signal Transduct Res 1999; 19: 191-202.
 
35) Jetschmann JU, Benschop RJ, Jacobs R, et al. Expression and in-vivo modulation of alpha-and beta-adrenoceptors on human natural killer (CD16+) cells. J Neuroimmunol 1997; 74: 159.
 
36) Landmann R: Burgisser E, Wesp M, et al. β-adrenergic receptors are different in subpopulations of human circulating lymphocytes. Journal of Receptor Reserch 1984; 4: 37-50.
 
37) Radojcic T, Baird S, Darko D, et al. Changes in beta-adrenergic receptor distribution on immunocytes during differentiation: An analysis of T cells and macrophages. J Neurosci Res 1991: 30: 328-335.
PubMed
38) Baerwald C, Graefe C, von Wichert P, et al. Decreased density ofβ-adrenergic receptors on peripheral blood mononuclear cells in patients with rheumatoid arthritis. J Rheumatol 1992; 19: 204-210.
 
39) Heijnen CJ, Rouppe van der V, Wulffraat N, et al. Functional α1-adrenergicreceptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. J Neuroimmunol 1996; 71: 223-226.
 
40) Felten DL, Felten SY, Bellinger DL, et al. Noradrenergic and peptidergic innervaton of secondary lymphoid or/gans: Role inexperimental arth ritis. Eur J Clin Invest 1992; 22 (suppl 1): 37-41.
 
41) 本郷道夫. 自律神経概説, 自律神経の基礎と臨床. 自律神経の基礎と臨床, 改定3版. 大阪, 医薬ジャーナル2006: 16-26.
 
42) Levine JD, Coderre TJ. β2 Adrenergic mechanisms in experimental arthritis. Proc. Natl. Acad. Sci USA 1988; 85. 4553-4556.
 
43) Geenen R, Godaert GL, Jacobs JW, et al. Diminished autonomic nervous system responsiveness in rheumatoid arthritis of recent onset. JRheumatol 1996; 23: 258-264.
PubMed
44) Louthrenoo W, Ruttanaumpawan P, Aramrattana A, et al. Cardiovascular autonomic nervous system dysfunction in patients with rheumatoid arthritis and systemic lupuserythematosus. QJM 1999; 92: 97-102.
 
45) Maule S, Quadri R, Mirante D, et al. Autonomic nervous dysfunction in systemiclupus erythematosus (SLE) and rheumatoid arthritis (RA): possible pathogenic role of autoantibodies to autonomic nervous structyres. Clin Exp Immunal 1997; 110: 423-427.
 
46) Anichkov DA. Heart rate variability is related to disease activity and smoking in rheumatoid arthritis patients. Int J Clin Pract 2007; 61 (5): 777-783.
PubMed
47) Straud RH, Baerwald CG, Wahle M, et al. Autonomic dysfunction in rheumatic disease. Rheuma Dis Clin N Am 2005; 31: 61-75.
 
48) Piha J. S, Voipio-Pulkki M-L. Elevared resting heart rate in rheumatoid arthritis: possible role of physical deconditioning, British Journalbof Rheumatology 1993; 32: 212-215.
 
49) 安保 徹. 気圧と疾患, (虫垂炎). 自律神経と免疫の法則, 1版. 東京, 三和書店, 2004: 1-6.
 
50) 安保 徹. 白血球膜上に発言する自律神経レセプターと白血球の生体リズム. 自律と免疫の法則, 1版. 東京, 三和書店, 2004: 7-13.
 
51) Toyabe S, Iiai T, Fukuda M, et al. Identification of nicotinic acetylcholine receptors on lymphocytes in periphery as well as thymus in mice. 1997. Immunology 1997; 92: 201-205.
PubMed
52) Tsukahara A, Toda T, Suzuki S, et al. Adrenergic stimulation simultaneously induces the expansion of granulocytes and extrathymic T cells in mice. Biomed Res 1997; 18: 237-246.
 
53) 安保 徹. 免疫系の年内リズム. 自律神経と免疫, 1版. 東京, 三和書店, 2004: 189-194.
 
54) 小宮靖弘. リウマチ病と気候. 七川歡次 (監修), リウマチ病セミナーXVII. 大阪, 永井書店, 2006: 70-75.
 
P.27 掲載の参考文献
1) Akiba S, Hyrayama T. Cigarette smoking and cancer mortality risk in japanese men and women Result from reanalysis of the six-prefecture cohort study data Emviron Healoth Perspect 1990; 87: 19-26.
 
2) 喫煙と健康-喫煙と健康問題に関する検討会報告書-. 東京, 保健同人社, 2002: 6.
 
3) 健康と医療の動向, 国民衛生の動向. 2007; 84-86.
 
4) 前田 晃. 煙草は骨・関節疾患に影響するか?七川歡次 (監修), リウマチセミナーXIII. 大阪, 永井書店, 2002: 55-65.
 
5) Mattey DL, Dawes PT, Angel M, et al. HLA-DRB1 alleles encording an aspartic acid at position 70 protect against development of rheumatoid arthritis: J Rheumatol 2001; 28: 232-239.
 
6) Mattey DL, Dawes PT, , Clarke S, et al, Relationship among the HLA-DRB1 shared epitope, smokimg, and rheumatoid factor production in rheumatoid arthritis. Arthritis Rheum 2002; 47: 403-407.
PubMed
7) Criswell LA, Merlino LA, Cerhan JR, et al. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: Results from the Iowa Womens Health stydy. Amer J Med 2002; 112: 465-471.
 
8) Stolt P, Bougtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthrtis: Ann Rheum Dis 2003; 62: 835-841.
 
9) Krishnan E, Sokka T, Hannonenp, et al. Smoking-gender interaction and risk for rheumatoid arthritis: Arthrtis Res Ther. 2003; 5: R158-162.
 
10) Krishnan E. Smoking, gender and rheumatod arthrits-Epidemiological clues to etiology. Joint Bone Spine; 2003; 70: 496-502.
 
11) Korpolahde T, Helovaan M, Knikt P, et al. Smoking history and serum cortinine and thiocyanate concentration as determinant of rheumatoid factor in non rheumatoid subjects. Rheumatklogy 2004: 43: 1424.
 
12) Padyukow L, Silva C, Stolt P, et al. A gene environment interaction between smoking and shared epitipe gene in HLA-DR provides a high risk to seropositive rheumatoid arthritis. Arthritis Rheum 2004; 56: 2713-2721.
 
13) Lee H, Irigoyen P, Kern M, et al. Interaction between smoking, the shared epitope, and anti-cyclic citullinated peptide. Arhtritis Rheum 2007; 56: 1745-1753.
 
14) Linn-Rasker SP, vander Helm-van Mil SP, van Gaalen FA, et al. Smokng is a risk factor for anti-ccp antibodies only in rheumatoid arthrits patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65: 366-371.
 
15) Jaakola JJ, Gissler M. Maternal smoking in pregnancy as a determinant rheumatoid arthritis and other inflammatory polyarthropathies during the first years of life. Int J Epidemiol 2005; 34: 664.
 
16) Pederse M, Jacobsen S, Klaelund, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic cirullinated peptides: Arthrits Research & therapy 2006: 8: R133.
 
17) Costenbader KH, Feskanich D, Mandl LA, et al. smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women: Amer J Med 2006; 119: 503-511.
 
18) Klareskog L, Padyukov L, Ronnelid J, et al. Genes, envionment and immunity in development of rheumatoid arthritis: Current Opinion in Rheumatology 2006; 18: 650-655.
 
19) Klareskog L, Stoly P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-R (shared epitope)-restricted immune reactions to autoantigens modifided by citrullination: Arthritis Rheum 2006; 54: 38-46.
 
20) Klareskog L, Padyukov L, Rorentzen J et al. Mechanisms of disease: genetic susceptibility anad envilonmental triggers in the development of rheumatoid arthritis. Rheumatolpgy 2006; 2: 425-433.
 
21) Klareskog L, Padyukov L & Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases: Current Opinion in Rheumatology 2007; 19: 49-54.
 
22) van der Helm-van MIL AHM, Wesoly JZ, Huizinga TMW. Understanding the genetic contribution to rheumatoid arthritis. Current opinion in Rheumatology 2005; 17: 299-304.
 
23) van der Helm-van Mil AMH, Verpoort KN, Cessie SL, et al. The HLA-DRB1 shared epotope alleles differ in the interaction with smoking and preposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007; 56: 425-432.
 
24) Pantopaa-Dahlovis S, de Long M, Holmdah R. Anti-bodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Ann Rheum Dis 2003: 48: 2741-2749.
 
25) Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 2004; 0: 380-386.
 
26) Plenge RM, Padyukov L Remmers EF, et al. Replication of putative candidate-gene association with rheumatoid arthritis in >4000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4: Amer J Hum Genet. 2005; 77: 1044-1060.
 
27) Albano SA, Santana-sahagun E, Weisman MK. Cigarette smoking and rheumatoid arthritis. Semin Arthrits Rheum 2001: 31: 146-159.
 
28) Wolfe F. The effect of smoking on cliical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000; 27: 630-637.
 
29) Saag KG, Cerhan JR, Kolluri S, et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum dis 1667; 56: 463-69.
 
30) Masdottir B, Jonsson T, Manfredsdottir A, et al. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology 2000; 39: 1202-1205.
PubMed
31) Harrison BJ, Silman AJ, Wiles NJ, et al. The association of cigarette smoking with disease outcome in patiens with early inflammatory polyarthrits. Arthritis Rheum 2001: 44: 323-330.
 
32) Matty DL, Hatchinson DmDaves PT, et al. Smoking and disease severity in rheumatoid arthrits. Arthrits Rheum 2002: 46: 640.
 
33) Bongartz T, Cantaert t, Atkins SR, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatolgy 2007; 46: 705.
 
34) Manfredsdottir VF, Vikingsdottir T, Jonnsson T, et al. The effect of tabacco smoking and rheumatoid facor seropositivity on disease activity and joint damage in early rheumatoid arthrtis. Rheumatology 2006: 45: 734-740.
 
35) Finckh A Dehler S, Costenbader KH, et al. Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1066-1071.
PubMed
36) Glossop JR, Dawes PT, Matty DL. Association between cigarette smoking and release of tumour necrosis factor alpha and its soluble receptors by peripheral blood mononucleal cells in patients with rheumatoid arthritis. Rheumatology 2006; 45: 1223-1229.
 
37) Hyrich KL, Watson KD, Silma AJ, et al. Predictions of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis. Rheumatology 2005; 44 (Suppl 1): i24.
 
38) Hyrich KL, Watson KD, Silma AJ, et al. Predictions of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologic Register. Rheumatology 2006: 45: 1558-1569.
 
39) Verpoort KM, Papendrecht-van der Voot EA, van der Helm-van Mil AM, et al. Associationof smoking with the constitution of the anti-cyclic citrullinated pepide response in the absence of HLA-DRB1 shared epitope alleles. Arhritis Rheum 2007; 56: 2913-2918.
 
40) Combe E. Early rheumatod arthrits: strategies for prevenntion and management: Biologic & Research Clinical Reumatology 2007: 21: 27-42.
 
41) 岩田康男,楊 鴻生, 厚井 薫ら.当科におけるリウマチ患者の喫煙状況:日本臨床リウマチ学会,2002. 11.発表
 
42) 鈴木王洋.喫煙と関節リウマチ. リウマチ科2006; 35: 213-218.
 
43) 土屋尚之.関節リウマチの環境要因. 医学の歩み2004: 209: 769.
 
P.35 掲載の参考文献
1) Coury C. Hippocratic fingers and hypertrophic osteoarthropathy. Br J Dis Chest 1960; 54: 202-209.
PubMed
2) 大川 司, 刀祢毅,衛藤光ら. Yellow nail症候群. 皮膚病診療1992; 14: 447-450.
 
3) Camilleri AE. Chronic sinusitis and the yellow nail syndrome. J Laryngol Otolog 1990; 104: 811-813.
 
4) Don PC, Fusco F, Fried P, et al. Nail dyschromia associated with zidovudine. Ann lnern Med 1990; 112: 145-146.
PubMed
5) Ban M, Kitajima Y. Nail discoloration occurring after 8 weeks of minocycline therapy. J Dermatol 2007; 34: 699-701,
PubMed
6) 東 禹彦. 匙状爪の発症機序. 皮膚1969; 27: 29-34.
 
7) Rich P, Scher R. Nail psoriasia severity index: A useful tool for evaluation of nail psoriasis. J Amer Acad Dermatol 2003; 49: 206-212.
 
8) 東 禹彦. 爪部に限局した炎症性疾患, 爪-基礎から臨床まで-. 東京, 金原出版, 2004: 194-198.
 
9) 渡辺晋一. 爪真菌症の診断, 爪真菌症マニュアル. 東京, 南江堂, 2005: 23-47.
 
10) Ohtuka T. The relation Periungual erythema and nailfold capillay abnormalities in patients with connective tissure diseases. Eur J Dermatol 1997: 7: 561-565.
 
11) Urowitz MB, Gladman DD, Charlmers A, et al. Nail lesions in systemic lupus erythematosus. J Rheumatol 1978; 5: 441-447.
 
12) Tosti A. The nail apparatus in collagen disorders. Smin Dermatol 1991; 10: 71-76.
 
13) 太田知子, 岡 大介, 植木宏明. 膠原病の爪囲紅斑. 西日皮膚1985; 47: 509-513.
 
14) 難病医学研究財団. 強皮症診断の手引き. 大正製薬株式会社, 1991: 6.
 
15) Samitz MH: Cuticular changes in dermatomyositis. Arch Dermatol 1974; 110: 866-867.
PubMed
16) Michel C, Cribier B, Sibilia J, et al. Nail abnormalitied in rheumatoid arthritis. Brit J Dermatol 1997; 137: 958-962.
 
17) Mttingly PC, Bossingham DH. Yellow nail syndrome in rheumatoid arthritis: report of three cases. Ann Rhem Dis 1979; 38: 475-478.
 
18) 吉野博子, 池田美智子, 南光弘子. ブシラミンとD-ペニシラミンにより誘発された爪甲の変化. 臨皮 1995; 49: 509-512.
 
19) 辻屋英信, 嵯峨賢次. Bucillamine内服中に生じた黄色爪. 皮膚臨床1997; 39: 1283-1286.
 
20) 田中宏幸, 松田正樹,野口 学ら. ブシラミンによる黄色爪症候群の1例. リウマチ科2006: 35: 309-313.
 
21) 日本医薬品集フォーラム: 日本医薬品集, 医療薬, 2008年版. 東京, じほう社, 2007: 1990-1992.
 
P.41 掲載の参考文献
1) 川崎 拓. 痛風の疫学, 七川歡次 (監修), リウマチ病セミナー―XVIII. 大阪, 永井書店, 2007: 51-57.
 
2) 大島良雄. 痛風の臨床. 日内会誌1965; 54: 291-310.
 
3) 山中 寿, 作山理子, 渡辺純子ら. 女性若年者における痛風-最近の動向. 高尿酸血症と痛風1994; 223-229.
 
4) 小松原良雄, 七川歡次, 前田 晃ら. 大阪地方における痛風症の現況. 中部整災誌1967; 10: 228-230.
 
5) 七川歡次.痛風の疫学. 内科MOOK 1983; 21: 22-31.
 
6) Kato H, Duff IF, Russell WJ, et al. Rheumatoid arthritis and gout in Hiroshima and Nagasaki. J Chron Dis 1971; 23: 659-679.
 
7) Nishioka K, Mikanagi K. Hereditary and environmental factors influencing on the serum uric acid throughout ten years population study in japar. Adv Exp Med Biol 1980: 22: 155-159.
 
8) Akizuki S. A population study of hyperuricemia and gout in Japan; analysis of sex, age and occupational differences in thirty-four thousand people living in Nagano prefecture. Rheumachi 1982; 22: 201-208.
PubMed
9) 塩 宏. 鳥取県における痛風の有病率. 高尿酸血症と痛風1994: 2: 113-115.
 
10) 川崎 拓, 七川歡次. 住民検診による痛風の疫学調査. 痛風と核酸代謝2006; 30: 66.
 
11) Adams PF, Hendershot GE, Marano MA. Centers for disease control and prevention/national center for health statistics. Current estimates from the National Health Interview Survey, 1996. Vital Health State 10. 1999: 200: 1-203.
PubMed
12) Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-272.
PubMed
13) Dai SM, Han XH, Zhao DB, et al. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol 2003; 30: 2090-2091.
 
14) 細谷龍男. 加齢性と高尿酸血症. プリン・ピリミジン代謝1995; 19: 140-143.
 
15) 藤森 新. 高尿酸血症・痛風の疫学と背景因子: 高尿酸血症・痛風は増え続けているか. プリン・ピリミジン代謝1997; 19: 123-133.
 
16) 細谷龍男, 市田公美, 畝村さゆみら. 長距離走による尿酸代謝の動態と性差. プリン・ピリミジン代謝 1994; 18: 11-17.
 
17) Adamopoulos D, Vlassopoulos C, Seitamides B, et al. The relationship of sex differences in uric acid metabolism in adult; 17β (E2) on the renal handling of urate. Metabolism 1986; 35: 343-388.
 
18) 作山理子, 山中 寿, 鎌谷直之ら. 本邦女性痛風患者43例の特徴. プリン・ピリミジン代謝1993: 17: 17-23.
 
19) Adam O, Goebel FD. Secondary gout and pseudo-Bartter syndrome in females with laxative abuse. Klin Wochenschr. 1987; 65: 833-839.
PubMed
20) 西澤和也, 今井晋二ら. 神経因性食思不振症の女性に合併した手指巨大痛風結節の1例. 整形外科2003; 54: 1419-1422.
 

骨関節,脊椎,神経

P.47 掲載の参考文献
1) GOLD DT. The clinical impact of vertebral fractures quality of life in women with ostteoporosis. Bone 1996; 18: 185S-189S.
PubMed
2) Silverman SI. The clinical consequences of vertebral comopression fracture. Bone 1992; 13: S27-31.
 
3) Bostrom MPG, Lane Jm. Future directions. Augmentation of osteoporotic vertebral bodies. Spine 1997; 26: 151-156. 4
 
4) Deramond H, Depriester C, Gailbert P, et al. Percutaneous vertebroplasty with polymethylmethacryalte. Technique, indication and results. Radiol Clin North Am 1998; 36: 533-546.
 
5) Lieberman IH, Dudeney S, Reinhardt MK, Bell G. Initial outcome and efficacy of"kyphoplasty"in the treatment of painful osteoporotic vertebral compression fracture. Spine 2001; 26: 1631-1638.
PubMed
6) Ito Y, Hasegawa Y, Todo K, Nakahara S. Pathogenesis and diagnosis of delayed vertebral collpase resulting from osteoporotic spinal fracture. Spine J 2002: 2: 101-106.
 
7) Gailbert P, Deramond H, Rosat O, et al. Note preliminaire sur le traitement desangiomes vertebraux par vertebroplastie percutanee. Neurochirurgie 1987; 33: 166-168.:
 
8) Dubosshe-Depriester C, Deramond H. Percutaneous vertebroplasty with acrylic cement inn the treatment of osteoporotic vertberal crush fracture syndrome. Neuroradiology 1991; 33: S49-S52, 1991.
 
9) Cotton A, Dewarte F, Cortet B, et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methylmethacrylate at clinical follow-up. Radiology 1996; 200: 525-530.
 
10) Konno S, Olmarker K, Byrod G, et al. The European Spine society AcroMed Prize 1994. Acute thermal nerve root injury. Eur Spine J 1994; 3: 299-302.
PubMed
11) Vasconcelos C, Gailloud P, Martin JB et al. Transient arterial hypotension induced by polymethylmethacrylate injection during percutaneous induced by polymethacryate injction during perutaneous vertebroplasty. Vasc Inerv Radiol 2001; 12: 1001-1002.
 
12) Ikeuchi M, Yamamoto H, Shibata T, et al. Mechanical sugmentation of the Vertebral body by calcium phosphate cement injection. J Orthop Sci 2001; 6: 39-45.
PubMed
13) Nakano M, Hirano N, Matsuura K, et al. Percutaneous transpedicular vertebroplasty with Calcium phosphate cement in the treatment of osteoporotic vertebral compression and burst fractures. J Neurosurg (Spine 3) 2002; 97: 287-293.
 
14) Hasegawa K, Homma T, Uchiyama S, Takahashi H. Vertebral pseudoarthorosis in the osteoporotic spine. Spine 1998; 23: 2201-2206.
 
15) Taylor RS, Taylor RJ, Fritzell P. Balloon kyphoplasty and vertebroplasty for vertebral compression fractures: a comparative systematic review of efficacy and safety. Spine 2006: 31: 2747-2755. Review.
PubMed
16) Diamond TH, Champion B, Clark WA. Management of acute osteoporotic vertebral fractures: A nonrandomized trial comparing percutaneous vertebroplasy with conservative therapy. The American Journal of Medicine 2003; 114: 257-265.
 
17) Nakamura H, Terai H, Tsujio T, et al. Factors predictive ofpseudoarthrosis following osteoporotic vertebral fracture-A prospective multicenter study-. The Journal of the Japanese Societyfor Spine Surgery and Related Research 2007; 18: 620-623.
 
P.55 掲載の参考文献
1) 吉原 紳. ゴルフ一番危険なスポーツ, 飛鳥新社, 1997.
 
2) 渡會公治. ゴルフとスポーツ障害・外傷. 治療2006; 88: 1709-1717.
 
3) Gosheger G, Liem D, Ludwig K, et al.: Injuries and overuse syndromes in golf. Am J Sports Med 2003; 31: 438-443.
PubMed
4) McCarroll JR, Gioe TJ. Professional golfers and the price they pay. Phys Sportsmed 1982; 10: 64-70.
PubMed
5) Sugaya H, Tsuchiya A, Moriya H, et al.: Low-back injury in elite and professional golfers an epidemiologic and radiographic study. In: Farrally MR, Cochran AJ, editor. Science and golf III: Proceedings of the World Scientific Congress of Golf; 1998, p20-24; St Andrews. Champaign (IL): Human Kinetics, 1998: 65-72.
 
6) McCarroll JR, Retting AC, Shelbourne KD. Injuries in the amateur golfer. Phys Sportsmed 1990; 18: 122-126.
 
7) Finch C, Sherman C, James T. The epidemiology of golf injuries in Victoria, Australia: evidence from sportsmedicine clinics and emergency department presentations. In: Fallally MR, Cochran AJ, editor. Science and golf III: Proceedings of the World Scientific Congress of Golf; 1998, p20-24; St Andrews. Champaign (IL): Human Kinetics, 73-82.
 
8) Batt ME. A survey of golf injuries in amateur golfer. Br J Sports Med 1992; 26: 63-65.
PubMed
9) Theriault G, Lacoste E, Gaboury M, et al.: Golf injury characteristics: a survey of 528 golfers [abstract]. Med Sci Sports Exerc 1996; 28: S65.
 
10) McNicholas MJ, Nielsen A, Knill-Jones RP. Golf injuries in Scotland. In: Fallally MR, Cochran AJ, editor. Science and golf III: Proceedings of the World Scientific Congress of Golf: 1998, p20-24; St Andrews. Champaign (IL): Human Kinetics, 65-72.
 
11) 岩本 潤, 竹田 毅. ゴルフプレイヤーの整形外科的傷害. 性差と医療2006; 3: 79-85.
 
12) Recreation: golf injuries. Harv Health Lett 2000; 25: 4-5.
PubMed
13) Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis. Results of a randomized, placebo-controlled, double-blind trial. Arthritis Reumatism 2005; 57: 2015-2025.
 
14) Khayyal MT, EI-Ghazaly MA. The possible "chondroprotective" effect of the unsaponifiable constituents of avocado and soya in vivo. Drugs Explt Clin Res 1998; 24: 41-50.
 
15) Hosea TM, Gratt CJ, Galli NA, et al. Biomechanical analysis of the golfer's back. In: Cochran AJ, editor. Science and golf I: Proceedings of the World Scientific Congress of Golf. St Andrews, London, E & FN Spon, 1990: 43-48.
 
16) Mets JP. Managing golf injuries: technique and equipment changes that aid treatment. Phys Sportsmed 1999; 27: 41-56.
 
17) Mackey S. The gojf swing and facet syndrome. Chiro Sports Med 1995; 9: 10-13.
 
18) McHardy A, Pollard H. Lower back pain in golfers: a review. J Chiro Med 2005; 3: 135-143.
 
19) Mundt DJ, Kelsey JL, Golden AL, et al. An epidemiologic study of sports and weight lifting as possible risk factors for herniated lumbar and cervical discs. Am J Sports Med 1993; 21: 854-857.
PubMed
20) McHardy A, Pollard H, Luo K. Golf injuries. A review of the literature. Sports Med 2006; 36: 171-187.
PubMed
21) Chao EY, Tamai K, Cahalan TD, et al. Biomechanics of the golf swing as related to club handle design. Biomech Sport 1987; 6: 107-111.
 
22) Cahalan TD, Cooney III WP, Tamai K, et al. Biomechanics of the golf swing in players with pathologic conditions of the forearm, wrist, and hand Am J Sports Med 1991; 19: 288-293.
 
23) Golfers: wrist. BMJ 1977; 2: 1622.
PubMed
24) Guha AR, Marynissen H. Stress fracture of the hook of the hamate. Br J Sports Med 2002; 36: 224-225.
PubMed
25) Skolnick AA. ‘Golfer's wrist' can be a tough break to diagnose. JAMA 1998: 279: 571-572.
 
26) Torisu T. Fracture of the hook of the hamate by a golfswing. Clin Orthop 1972: 83: 91-94.
PubMed
27) Aldridge JM, Mallon WJ. Hook of the hamate fracyures in competitive golfers: results of treatment by excision of the fractured hook of the hamate. Orthopedics 2003; 26: 717-719.
PubMed
28) Walsh JJ, Bishop AT. Diagnosis and management of hamate hook fracyures. Hand Clin 2000; 16: 397-403.
PubMed
29) Murray PM, Coobey WP, Golf-induced injuries of the wrist. Clin Sports Med 1996; 15: 85-109.
 
30) Hsu WC, Chen WH, Oware A, et al. Unusual entrapment neuropathy in a golf player. Neurology 2002: 59: 646-647.
 
31) Mueller LP, Mueller LA, Degreif J. Hypothenar hammer syndrome in a golf player: a case report. Am J Sports Med 2000; 28: 741-745.
 
32) McHardy A, Pollard H. Case report: unusual cause of wrist pain in a golfer. Br J Sports Med 2004; 38: e34.
 
33) Glazebrook MA, Curwin S, Islam MN, et al. Medial epicondylitis: an electromyographic analysis and an investigation of intervention strategies. Am J Sports Med 1994; 22: 674-679.
 
34) Stover CN, Wiren G, Topaz SR. Modern golf swing and stress syndromes. Phys Sportmed 1976; 4: 42-47.
 
35) Loftice J, Fleisig GS, Zheng N, et al. Biomechanics of the elbow in sports. Clin Sports Med 2004; 23: 519-530.
PubMed
36) Stockard AR. Elbow injuries in golf. J Am Osteopath Assoc 2001; 101: 509-516.
PubMed
37) Hill JA. Epidemiologic perspective on shoukder injuries. Clin Sports Med 1983: 2: 241-246.
PubMed
38) Kim DH, Millett PJ, Warner JJ, et al. Shoulder injuries in golf. Am J Sports Med 2004; 32: 1324-1330.
PubMed
39) Mitchell K, Banks S, Morgan D, et al. Shoulder motions during the golf swing in male amateur golfers. J Orthop Sports Phys Ther 2003; 33: 196-203.
PubMed
40) Mallon WJ, Colosimo AJ. Acromioclavicular joint injury in competitive golfers. J South Orthop Assoc 1995; 4: 277-282.
PubMed
41) Hovis WD, Dean MT, Mallon WJ, et al. Posterior instability of the syoulder with secondary impingement in elite golfers. Am J Sports Med 2002; 30: 886-890.
PubMed
42) Bell R, Acus R, Noe D. A study of acromioclavicular forces. J Shoulder Elbow Surg 1993: 2 (Suppl. 1-2): s24.
 
43) Gatt Jr CJ, Pavol Mj, Parker RD, et al. Three-dimensional knee joint kinetics during a golf swing: influences of skill level and footwear. Am J Sports Med 1998; 26: 285-294.
 
44) Mallon WJ, Callaghan JJ. Total joint replacement in active golfers. J South Orthop Assoc 1994; 3: 295-298.
PubMed
45) Mallon WJ, Callaghan JJ. Total knee arthroplasty in active golfers. J Arthroplasty 1993; 8: 299-306.
PubMed
46) Knapp TP, Garrett WE. Stress fractures: general concepts. Clin Sports Med 1997; 16: 339-356.
PubMed
47) Maitra RS, Johnson DL. Stress fractures: clinical history and physical examination. Clin Sports Med 1997; 16: 259-274.
PubMed
48) Ha KI, Hahn SH, Chung MY, et al. A clinical study of stress fractures in sports activities. Orthopedics 1991: 14: 1089-1095.
PubMed
49) Lin HC, Chou CS, Hsu TC. Stress fractures of the ribs in amateur golf players. Clin Med J 1994; 54: 333-337.
 
50) Lord MJ, Ha KI, Song KS. Stress fractures of the ribs in golfers. Am J Sports Med 1996: 24: 118-122.
PubMed
51) Read MT. Case report-stress fracture of the rib in a golfer. Br J Sports Med 1994; 28: 206-207.
 
P.66 掲載の参考文献
1) リウマチ病I～VIII. 七川歡次編集, 大阪, 永井書店, 1971, 1973, 1975, 1977, 1979, 1982, 1984, 1986.
 
2) リウマチ病セミナーI～XX. 七川歡次監修, 大阪, 永井書店, 1990～2008 (毎年発行).
 
3) 第1回～第18回講演集 近畿リウマチ病研究会. 七川歡次 (第1回～第18回), 根来茂 (第1回～第3回), 志水正敏 (第4代～第18回) 監修, 東京, 癌と化学療法社 (第1回～第7回), 堺, 近畿リウマチ病研究会 (第8回～第17回), 西宮, 近畿リウマチ病研究会 (第18回), 1991～2008.
 
4) 本郷一郎. 結合組織炎症候群. 七川歡次 (監修), リウマチ病セミナーI. 大阪, 永井書店, 1990: 95-111.
 
5) 西岡淳一. Fibromyalgiaのレゾンデートル. 七川歡次 (監修), リウマチ病セミナーV. 大阪, 永井書店, 1994: 69-77.
 
6) 行岡正雄. Fibromyalgia (2002) その診断と治療.七川歡次 (監修), リウマチ病セミナーXIV. 大阪, 永井書店, 2003: 49-58.
 
7) 真下 節. 慢性痛の病態と治療- Complex Regional Pain Syndrome (CRPS) を中心に-七川歡次 (監修), リウマチ病セミナーIX. 大阪, 永井書店, 1998: 197-206.
 
8) 真下 節. 求心路遮断性疾痛症候群 (deafferentation pain syndrome). 七川歡次 (監修), リウマチ病セミナーX. 大阪, 永井書店, 1999: 280-291.
 
9) 野口光一. 痛みの神経生物学. 七川歡次, 志水正敏 (監修), 第12回講演集 近畿リウマチ病研究会. 堺, 近畿リウマチ病研究会, 2002: 47-54
 
10) 牛田享宏. 整形外科疾痛の中枢メカニズム. 七川歡次, 志水正敏 (監修), 第15回講演集 近畿リウマチ病 研究会. 堺市, 近畿リウマチ病研究会, 2005: 37-45.
 
11) 細井昌子. 慢性疼痛の認知行動療法-痛み認知と痛み行動へのアプローチ-七川歡次 (監修), リウマチ病セミナーXVII. 大阪, 永井書店, 2006: 181-188.
 
12) 森岡正博. 精神的な痛みと無痛文明. 七川歡次, 志水正敏 (監修), 第18回講演集 近畿リウマチ病研究会. 西宮, 近畿リウマチ病研究会, 2008: 43-47.
 
13) 三木健司, 行岡正雄. IV特殊な疾痛性疾患 3. 線維筋痛症. 山下敏彦 (編集), 運動器の痛みハンドブッ ク. 東京, 南江堂, 2007: 255-265.
 
14) Croft P. 15. Soft tissue rheumatism. Fibromyalgia. In Epidemiology of the rheumatic disease. (Silman A, Hochberg MC. ed.) Oxford, Oxford University Press, 1993: 408-421.
 
15) Sheon RP, Moskowitz RW, Goldberg VM 7: Fibromyalgia and other generalized soft tissue rheumatic disorder. In Soft tissue rheumatic pain: recognition, management, and prevention, 3rd ed. Baltimore, Williams & Wilkins, 1996: 275-305.
 
16) Freundlich B, Leventhal LC. ビまん性疾痛症候群. リウマチ入門 第11版[日本語版] (日本リウマチ学会編集). 1999: 170-176 (非売品).
 
17) Wallace DJ, Clauw DJ, ed. Fibromyalgia and other central pain syndromes, 1st ed. Philadelphia, Lippincott Williams & Wilkins, 2005.
 
18) 西岡久寿樹 (編集). 線維筋痛症ハンドブック. 東京, 日本医事新報社, 2007.
 
19) 宮岡 等. 精神医学からみた疾痛. 西岡久寿樹 (編集), 線維筋痛症ハンドブック. 東京, 日本医事新報社, 2007: 47-53.
 
20) 松本美富士. 線維筋痛症の疫学. 西岡久寿樹 (編集), 線維筋痛症ハンドブック. 東京, 日本医事新報社, 2007: 56-69.
 
21) 西林保朗, 久保仁志, 一色史章. サイコリウマトロジー事始-関節リウマチの在宅ケアと介護-神戸学院総合リハビリテーション研究 2008; 3: 3-14.
 
22) 厚生統計会編集. 第4章 健康と受療状況. 1. 健康状態1) 有訴者の状況. 2. 通院者の状況. 国民の動向・厚生の指標 2008; 臨時増刊・第55巻打第9号 通巻第864号: 72-73.
 
23) 土肥修司. 慢性痛はなぜ起こるか?西岡久寿樹 (編集), 線維筋痛症ハンドブック. 東京, 日本医事新報社, 2007: 14-25.
 
24) 西海正彦. E線維筋痛症候群. リウマチ基本テキスト第2版 (財団法人日本リウマチ財団教育研修委員会 編), 東京, 財団法人日本リウマチ財団, 2005: 496-499.
 
25) 行岡正雄, 三木健司. 線維筋痛症の病態の把握. 西岡久寿樹 (編集), 線維筋痛症ハンドブック. 東京, 日 本医事新報社, 2007: 70-81.
 
26) 西林保朗, 小形晶子. 筋筋膜痛症候群. 七川歡次 (監修), リウマチ病セミナーXVII. 大阪, 永井書店, 2006: 101-113.
 
27) Goldenberg DL Fibromyalgia and related syndromes. In Rheumatology, 3rd ed (Hochberg MC, Silman AJ, Smolen JF, et al ed). Edinburgh, Mosby, 2003: 701-712.
 
28) Pamuk ON, Tepil Y, Cakir N. Factors that affect the number of tender point in fibromyalgia and chronic widespread pain patients who did not meet the ACR 1990 criteria for fibromyalgia: Are tender points a reflection of neuropathic pain?Semin Arthritis Rheum 2006; 36: 130-134.
 
29) Yunus MB. The concept of central sensitivity syndrome. In Fibromyalgia and other central pain syndrome (Wallace DJ, Clauw DJ. ed). Philadelphia Lippincott Williams & Wilkens, 2005: 29-44.
 
30) 臼井千恵.線維筋痛症におけるコンサルテーション・リエゾン精神医学. 西岡久寿樹 (編集), 線維筋痛症 ハンドブック. 東京, 日本医事新報社, 2007: 152-156.
 
31) 金森 修. 科学的医学の周辺に潜む者への配意-摂食障害を事例として. 七川歡次, 志水正敏 (監修), 第13回講演集近畿リウマチ病研究会. 堺, 近畿リウマチ病研究会, 2007: 47-50.
 
32) 木村 敏医学への主観の導入. 七川歎次, 志水正敏 (監修), 第14回講演集近畿リウマチ病研究会. 堺, 近畿リウマチ病研究会, 2004: 45-48.
 
33) 田崎美弥子. 臨床面におけるスピリチュアリティー. 七川歡次, 志水正敏 (監修), 第16回講演集近畿リウマチ病研究会. 堺, 近畿リウマチ病研究会, 2006: 57-59.
 
P.72 掲載の参考文献
1) 有村公良, 樋口逸郎. 内科学 (杉本恒明・小俣政男総編集). 東京, 朝倉書店. 1999: 2009-2011.
 
2) Barker RA, Revesz T, Thom M, et al. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 1998: 65: 633-640.
PubMed
3) Brown P, Marsden CD. The stiff man and stiff man plus syndromes. J Neurol 1999; 246: 648-652.
PubMed
4) Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999; 131: 522-530.
PubMed
5) Dalakas MC, Fujii M, Li M, et al. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 2000; 55: 1531-1535.
PubMed
6) Raju R, Foote J, Banga JP, et al. Analysis of GAD65 autoantibodies in Stiff-person syndrome patients J Immunol 2005; 175: 7755-7762.
PubMed
7) Molloy FM, Dalakas MC, Floeter MK. Increased brainstem excitability in stiff-person syndrome. Neurology 2002; 59: 449-451.
PubMed
8) Sandbrink F, Syed NA, Fujii MD, et al. Motor cortex excitability in stiff-person syndrome. Brain 2000; 123: 2231-2239.
PubMed
9) Levy LM, Levy-Reis I, Fujii M, et al. Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 2005; 62: 970-974.
PubMed
10) Dinkel K, Meinck HM, Jury KM, et al. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998; 44: 194-201.
PubMed
11) Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58: 96-107.
PubMed
12) Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 2000: 26: 307-312.
PubMed
13) Raju R, Rakocevic G, Chen Z, et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 2006; 129: 3270-3276.
PubMed
14) Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol 2004; 61: 902-904.
PubMed
15) Nguyen-Huu BK, Urban PP, et al. Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer. Mov Disord 2006; 21: 1285-1287.
PubMed
16) Perani D, Garibotto V, Moresco RM, et al. PET evidence of central GABAergic changes in stiff-person syndrome. Mov Disord 2007: 22: 1030-1033.
PubMed
17) Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 2005; 252 Suppl 1: 19-25.
 
18) Baker MR, Das M, Isaacs J, et al. Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 2005; 76: 999-1001.
PubMed
19) Holmoy T. Long-term effect of gabapentin in stiff limb syndrome: acase report. Eur Neurol 2007: 58: 251-252.
 
P.80 掲載の参考文献
1) Urist MR. Bone formation by autoinduction. Science 1965; 150: 893-899.
PubMed
2) Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation.: molecular clones and activities. Science 1988; 242: 1528-1534.
PubMed
3) Yoshikawa H. Possible roles of bone morphogenetic proteins and transforming growth factors in the pathogenesis of OPLL and OLF. In. OPLL, 2nd ed. Tokyo, Springer, 2006: 59-63.
 
4) Yoshikawa H, Kameyama M, Ueda T, et al. Ossifying intramuscular metastasis from colon cancer: report of a case. Dis Colon Rectum 1999; 42: 1225-1227.
PubMed
5) Lee JS, Fetsch JF, Wasdhal DA, et al. A review of 40 patients with extraskeletal osteosarcoma. Cancer 1995; 76: 2253-2259.
PubMed
6) Okuda S, Myoui A, Nakase T, et al. Ossification of the ligamentum flavum associated with osteoblastoma: a report of three cases. Skeletal Radiol 2001; 30: 402-406.
PubMed
7) Smith R. Fibrodysplasia (myositis) ossificans progressiva. Clinical lessons from a rare disease. Clin Orthop 1998: 346: 7-14.
PubMed
8) 橋本 淳. myositis ossificans progressiva (fibrodysplasia ossificans progressiva). 七川歡次 (監修), リウマチ病セミナーXI. 大阪, 永井書店, 2000: 45-51.
 
9) Chang H, Brown CW, Matzuk MM Genetic analysis of the mammalian transforming growth factor-β superfamily. Endocr Rev 2002: 23: 787-823.
 
10) Tsumaki N, Yoshikawa H. The role of bone morphogenetic proteins in endochondral bone formation. Cytokine Growth Factor Reviews 2005: 16: 279-285.
PubMed
11) Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006; 7: 51-65.
PubMed
12) Onichtchouk D, Chen TG, Dosch R. Silencing of TGF-βsignaling by the pseudoreceptor BAMBI. Nature 1999; 401: 480-485.
 
13) Takase M, Imamura T, Sampath TK, et al. Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun 1998: 244: 26-29.
PubMed
14) Zhu H, Kavsak P, Abdollah S, et al. A Smad ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999; 400: 687-693.
PubMed
15) Kaplan FS, Tabas JA, Zasloff MA, et al. Fibrodysplasia ossificans progressiva: a clue from the fly? Calcif Tissue Int 1990; 47: 117-125.
PubMed
16) Shafritz AB, shore EM, Gannon FH, et al. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 1996; 335: 555-561.
PubMed
17) Fontaine K, Semonin O, Legarde JP, et al. A new mutation of the noggin gene in a French fibrodysplasia ossificans progressive (FOP) family. Genet Couns 2005; 16: 149-154.
 
18) Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006; 38: 525-527.
PubMed
19) 片桐岳信, 福田 亨, 鹿又一洋ら: BMPシグナルと骨疾患: 進行性骨化性線維異形成症 (FOP), The Bone 2007; 21: 711-715.
Medical*Online
20) Nakajima M, Haga N, Tanikawa K, et al. The ACVR1617G>A mutation is also recurrent in three Japanes patients with fibrodysplasia ossificans progressive. J Hum Genet 2007: 52: 473-475.
 
21) Feldman GJ, Billings PC, Patel RV, et al. Over-expression of BMP4 and BMP5 in a child with axial skeletal malformations and heterotopic ossification: a new syndrome. Am J Med Genet 2007; 143: 699-706.
 
P.88 掲載の参考文献
1) 浅嶌周造, 川合寛道, 初田直樹ら. 脳脊髄液減少症 (低髄液圧症候群) の治療経験.整形外科2007; 58: 317-321.
 
2) 美馬達夫. 脳脊髄液減少症-髄液漏れによる病態とブラッドパッチ治療におけるケア-. 月間ナーシング 2007; 27: 78-85.
 
3) 大原久美子, 関要次郎, 前田隆寛ら. 原発性低髄液圧症候群に合併した慢性硬膜下血腫の2例. 脳外 1984; 12: 1203-1208.
 
4) Pannullo SC, Reich JB, Krol G, et al. MRI changes in intracranial hypotension. Neurology 1993; 43: 919-926.
PubMed
5) Schievink WI. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. JAMA 2006; 295: 2286-2296.
PubMed
6) 宮澤康一. 特発性低髄液圧症候群の診断と治療. 脳神経2004: 56: 34-40.
 
7) 木下泰伸, 寺下俊雄, 寺田友昭ら. 激しい頭痛で発症し, 特徴的な神経放射線学的所見を呈した spontaneous intracranial hypotensionの2例. 脳外1997: 25: 437-442.
 
8) 山内浩揮, 大久保一浩, 安藤雅樹ら. 不幸な転帰をたどった低髄液圧症候群の1症例. 麻酔2003; 52: 88.
 
9) Mokri B. Spontaneous cerebrospinal fluid leaks: from intracranial hypotension to cerebrospinal fluid hypovolemia-evolution of a concept. Mayo Clin Proc 1999: 74: 1113-1123.
PubMed
10) 遠藤健司, 山本謙吾, 内田健二ら. 外傷性頸部症候群と特発性低髄液圧症候群臨整外2007: 42: 983-993.
 
11) 笹部哲哉, 進藤勝久, 種子田護ら. 頭部外傷後遺症および鞭打ち損傷後遺症の一断面 -外傷性慢性低脳圧症候群と治療的酸素気脳術について-, 脳神経1968: 20: 959-963.
 
12) 馬場久敏. 外傷性頸部症候群: むち打ち損傷に関する脊椎脊髄外科学的一見解. 脊椎脊髄2006: 19: 369-377.
 
13) 脳脊髄液減少症研究会ガイドライン作成委員会. 脳脊髄液減少症ガイドライン2007. 東京, メディカルレ ビュー社, 2007: 15-18.
 
14) 篠永正道. 低髄液圧による頭痛. 医学のあゆみ2005; 215: 1166-1170.
 
15) 岡崎 翼, 日野原圭, 西嶋康一ら. 精神科臨床で経験した脳脊髄液減少症の1例. 精神誌2005; 107: S-285.
 
16) Takagi K, Bolke E, Peiper M, et al. Chronic headache after cranio-cervical trauma-hypothetical pathomechanism based upon neuroanatomical considerations. Eur J Res 2007; 12: 249-254.
PubMed

検査法

P.97 掲載の参考文献
1) Albright F, Smith PH, Richadson AM. Postmenopausal osteoporosis: its clinical features. JAMA 1941; 116: 2465-2474.
 
2) Cheng XG, Nicholson PH, Boonen S, et al. Prediction of vertebral strength in vitro by spinal bone densitometry and calcaneal ultrasound. J Bone Miner Res 1997: 12: 1721-1728.
 
3) Turner CH. Yield behavior of cancellous bone. J Biomech Eng 1989; 111: 1-5.
PubMed
4) Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195-202.
PubMed
5) Riggs BL, O' Fallon WM, Lane A et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 1994; 9: 265-275.
PubMed
6) van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-787.
PubMed
7) Hui SL, Slemenda CW, Johnston CCJ. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81.
 
8) Selby PL, Davis M, Adams JE. Do men and women fracture bones at similar bone densities? Osteoporosis Int 2000; 11.
 
9) Cauley JA, Lui LY, Ensrud KE, et al. Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA 2005: 293: 2102-2108.
PubMed
10) NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795.
PubMed
11) Watts NB. Bone quality; getting closer to a definition. J Bone Miner Res 2002; 17: 1148-1150.
PubMed
12) Bouxsein ML. Bone quality; where do we go from here? Osteoporosis Int 2003; 14 (suppl.5): 118-127.
 
13) Norton R, Campbell AJ, Lee-Joe T, et al. Circumstances of falls resulting in hip fractures among older people. J Am Geriatr Soc 1997; 45: 1108-1112.
 
14) Caler WE, Carter DR. Bone creep-fatigue damage accumulation. J Biomech 1989; 22 (6-7): 625-635.
 
15) Bredbenner TL, Davy DT. The effect of damage on the viscoelastic behavior of human vertebral trabecular bone. J Biomech Eng 2006; 128: 473-480.
PubMed
16) Cristofolini L, Viceconti M, Cappello A, et al. Mechanical validation of whole bone composite femur models. J Biomech 1996; 29: 525-535.
PubMed
17) Tanabe Y, Tanaka S, Sakamoto M, et al. Determination of a viscoelastic model of bone. Theor Appl Mech 1991: 40: 259-266.
 
18) Prendergast PJ. Finite element models in tissue mechanics and orthopaedic implant design. Clin Biomech (Bristol, Avon) 1997; 12: 343-366.
PubMed
19) Bessho M, Ohnishi I, Okazaki H, et al. Prediction of the strength and fracture location of the femoral neck by CT-based finite-element method; a preliminary study on patients with hip fracture. J Orthop Sci 2004; 9: 545-550.
 
20) 真柴 賛. 骨の微細構造 骨強度の評価-力学的な骨質とは-. 日本臨牀2007; 65: 184-188.
 
21) Seeman E. Periosteal bone formation-a neglected determinant of bone strength. N Engl J Med 2003: 349: 320-323.
PubMed
22) Mayhew P, Thomas CD, Clement JG, et al. Relation between age, femoral neck cortical stability, and hip fracture risk. Lancet 2005; 366: 129-135.
PubMed
23) Beck TJ, Looker AC, Ruff CB, et al. Structural trends in the aging femoral neck and proximal shaft; analysis of the third national health and nutrition examination survey dural-energy X-ray absorptiometry data. J Bone Miner Res 2000; 15: 2297-2304.
 
24) 高田潤一, 射場浩介, 竹林康雄ら. DXA法による大腿骨近位部の骨強度評価の確立. Osteoporosis Japan; 2006; 311-313.
 
25) Duan Y, Wang XF, Evans A, et al. Structual and biomechanical basis of racial and sex differences in vertebral fragility in Chinese and Caucasians. Bone 2005; 36: 987-998.
 
26) Mautalen CA, Vega EM, Einhorn TA. Are the etiologies of cervical and trochanteric hip fractures different? Bone [suppl] 1996; 18: S133-137.
 
27) Genant HK, Delmas PD, Chen P, et al. Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 2007; 18: 69-76.
PubMed
28) Ito M, Ejiri S, Jinnai H et al. Bone structure and mineralization demonstrated using synchrotron radiation computed tomography (SR-CT) in animal models: preliminary findings. J Bone Miner Metab 2003; 21: 287-293.
PubMed
29) Bauer DC, Ewing SK, Cauley JA, et al. Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study. Osteoporos Int 2007; 18: 771-777.
PubMed
30) Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996; 348 (9026): 511-514.
PubMed
31) 楊鴻生. 踵骨: DXA (Heel scan), QUS. 日本臨牀2007: 65: 163-170.
 
32) Wehrli F, Hwang S, Ma J, et al. Cancellous bone volume and structure in the forearm; noninvasive assessment with MR microimaging and image processing. Radiology 1998; 206: 347-357.
PubMed
33) Iita N, Kose K. Development of a compact MRI for measurement of trabecular bone microstructure of the finger. Magn Res Med 2007; 57: 272-277.
 
34) Chestnut CH III, Majumdar S, Newitt DC, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging; results from the QUEST study. J Bone Miner Res 2005; 20: 1548-1561.
 
35) Krug R, Banerjee S, Han ET, et al. Fasibility of in vivo structural analysis of high-resolution magnetic resonance images of the proximal femur. Osteoporos Int 2005: 16: 1307-1314.
PubMed
36) Ito M, Ikeda K, Nishiguchi M, et al. multi-detector-row CT imaging of vertebral microstructure for evaluation of fracture risk. J Bone Miner Res 2005; 20: 1828-1836.
 
37) Graeff-C, Timm W, Nickelsen TN, et al. Teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 2007; 22: 1426-1433.
PubMed
38) Khosla S, Riggs BL, Atkinson EJ, et al. Effects of sex and age on bone microstructure at the ultradistal radius: A population-based noninvasive in vivo assessment. J Bone Miner Res 2006; 21: 124-131.
 
39) Lane NE, Thompson JM, Strewler GJ, et al. Intermittent treatment with human parathyroid hormone (hPTH [1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J Bone Miner Res 1995; 10: 1470-1477.
 
40) Kinney JH, Ladd AJ. The relationship between three-dimentional connectivity and the elastic properties of trabecular bone. J Bone Miner Res 1998; 13: 839-845.
 
41) Haire TJ, Hodgskinson R, Ganney PS, et al. A comparison of porosity, fabric and fractal dimension as predictors of the Young's modulus of equine cancellous bone. Med Eng Phys 1998; 20: 588-593.
 
42) Ikeda S, Tsurukami H, Ito M, et al. Effect of trabecular bone contour on ultimate strength of lumbar vertebra after bilateral ovariectomy in rats. Bone 2001: 28: 625-633.
PubMed
43) Zysset PK. A review of morphology-elasticity relationships in human trabecular bone: theories and experiments. J Biomech 2003; 36: 1469-1485.
PubMed
44) Ito M, Nishiada A, Aoyagi K, et al. Effects of risedronate on trabecura microstructure and biomechanical properties in ovariectomized rat tibia, Osteoporosis Int 2005; 16: 1042-1048.
 
45) Crawford RP, Cann CE, Keaveny TM. Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography. Bone 2003; 33: 744-750.
PubMed
46) Melton LJ, 3rd, Riggs BL, Keaveny TM, et al. Structural determinants of vertebral fracture risk. J Bone Miner Res 2007: 22: 1885-1892.
 
47) Keaveny TM, Donley DW, Hoffmann PF, et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007; 22: 149-157.
 
48) 馬渡太郎, 三浦裕正, 濱井 敏ら. 代謝性骨疾患における骨質評価の最前線-骨微細構造と骨強度からのアプローチ. 日本骨形態計測学会雑誌2007: 17: 59-64.
 
49) Wigderowitz CA, Paterson CR, Dashti H, et al. prediction of bone strength from cancellous structure of the distal radius; can we improve on DXA? Osteoporos Int 2000: 11: 840-846.
PubMed
50) Robinson RA, Watson ML. Collagen crystal relationships in bone as seen in the electron microscopy. Anat Res 1952: 114: 383-410.
 
51) Saito M, Soshi S, Fujii K. Effect of hyper-and microgravity on collagen post-translational controls of MC3T3-E1 osteoblasts. J Bone Miner Res 2003; 18: 1695-1705.
PubMed
52) Saito M, Mori S, Mashiba T, et al. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos lnt, in press.
 
53) Saito M, Fujii K, Soshi S et al. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation induced pentosidine in the femoral neck cortex in case of femoral neck fracture. Osteoporosis Int 2006; 17: 986-995.
 
54) Paschalis EP, Shane E, Lyritis G, et al. Bone fragility and collagen cross-links. J Bone Miner Res 2004; 19: 2000-2004.
 
55) Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007; 40: 1144-1151.
PubMed
56) Saito M, Marumo K, Fujii K, et al. Single column high-perfomance liquid chromatographic-fluorescence detection of immature, mature and senescent cross-links of collagen. Anal Biochem 1997; 253: 26-32.
 
57) Lubec B, Fang-Kircher S, Lubec T, et al. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria Biochim Biophys Acta 1996: 1315: 159-162.
PubMed
58) Mclean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350: 2042-2049.
 
59) 斉藤 充. 代謝性骨疾患における骨質評価の最前線-コラーゲン解析のアプローチ. 日本骨形態計測学会雑誌2007; 17: 53-58.
 
60) Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J bone Miner Res 2004: 19: 999-1005.
 
61) Allen MR, Burr DB. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007; 22: 1759-1765.
PubMed
62) Durchschlag E, Paschalis EP, Zoehrer R, et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3-and 5-year treatment with risedronate. J Bone Miner Res 2006; 21: 1581-1590.
PubMed
63) 真柴 賛骨質の評価-骨質と薬物療法の意義. Clinical Calcium 2008; 18: 300-307.
 
64) Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85: 214-218.
 
65) Mann V, Huber C, Kogianni G, et al. The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007; 40: 674-684.
PubMed
66) Paschalis EP, Boskey AL, Kassem M, et al. Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res 2003: 18: 955-959.
 
67) Sanada H, Shikata J, Hamamoto H, et al. Changes in collagen cross-linking and lysyl oxidase by estrogen. Biochim Biophys Acta 1978; 541: 408-413.
PubMed
68) Saito M, Soshi S, Tanaka T, et al. Effects of Vitamins B6 and K20 on Bone Mechanical Properties and Collagen Cross-Links in Spontaneously Diabetic WBN/Kob Rats. J Bone Miner Res supple: SU420, 2005.
 
69) 骨粗鬆症診療における骨代謝マーカーの適正使用に関する検討委員会. 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン (2004年度版). Osteoporosis Jpn 2004: 12: 191-238.
 
70) Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers Of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526-1536.
PubMed
71) Van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350: 2033-2041.
PubMed
72) Vergnaud P, Garnero P, Meunier PJ, et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study. J Clin Endocrinol Metab 1997; 82: 719-724.
PubMed
73) 三木隆己, 正木秀樹. 骨の代謝回転. 日本臨牀2007; 65: 189-193
 
P.106 掲載の参考文献
1) Van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002; 60: 383-388.
PubMed
2) Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab 2002: 21: 34-36.
PubMed
3) Pinheiro GC, Scheinberg MA, Aparecida-da Silva M et al. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med 2003; 139: 234-235.
PubMed
4) Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62: 870-874.
PubMed
5) Suzuki K, Sawada T, Murakami A, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003; 32: 197-204.
PubMed
6) Dubucquoi S, Solau-Gervais E, Lefranc D, et al. Evaluation of anti-citrullinated fillaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004; 63: 415-419.
PubMed
7) De Rycke L, Peene I, Hoffman IEA, et al. Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004; 63: 1587-1593.
PubMed
8) 松野博明. Anticitrulline-containing peptide antibody. 七川歡次 (監修), リウマチ病セミナーXIV. 大阪 永井書店, 2003: 96-101.
 
9) 塩沢俊一. 新しい自己抗体. 七川歡次 (監修), リウマチ病セミナーXV. 大阪, 永井書店, 2004: 129-141.
 
10) Symmons DPM, Hazes JMW, Silman AJ. Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis. . J Rheumatol 2003; 30: 902-904.
 
11) Bell DA. Can we rely on anti-citrulline antibody determination for the diagnosis of early rheumatoid arthritis. J Rheumatol 2006; 33: 2369-2371.
PubMed
12) Yamane T, Hashiramoto A, Tanaka Y, et al. Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count and C-reactive protein/ rheumatoid factor. J Rheumatol, 2008: 35: 414-420.
 
13) Tamaki M, Kawakami A, Uetani M, et al. Early prediction of rheumatoid arthritis by serological variables and magnetic resonance imaging of the wrists and finger joints: results from prospective clinical examination. Ann Rheum Dis 2006; 65: 134-135.
 
14) Hueber W, Tomooka BH, Zhao X, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoantibody is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007; 66: 712-719.
PubMed
15) Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis. Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrunination. Arthritis Rheum 2006; 54: 38-46.
 
16) Lee H-S, Irigoyen P, Kern M, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide. Arthritis Rheum 2007; 56: 1745-1753.
PubMed
17) Van der Helm-van Mil AHM, Verpoort KN, le Cessie S, et al. The HLA-DRB1 shared epitope alles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007; 56: 425-432.
 
18) Kallberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80: 867-875.
 
19) Irigoyen P, Lee AT, Wener MH, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005; 52: 3813-3818.
PubMed
20) Ferucci ED, Majka DS, Parrish LA, et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2005: 52: 239-246.
PubMed
21) Hill JA, Southwood S, Sette A, et al. The conversion of arginine to citrulline allows for high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171: 538-541.
PubMed
22) Vossenaar ER, Smeets TJM, Kraan MC, et al. The presence of citrullinated proteins is not specific for rheumatoid arthritis tissue. Arthritis Rheum 2004; 50: 3485-3494.
 
23) Pratesi F, Tommasi C, Anzilotti C, et al. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 733-741.
PubMed
24) Hill JA, Al-Bishri J, Gladman DD, et al. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 2115-2119.
PubMed
25) Avouac J, Gossec L, Dougados M, Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65: 845-851.
PubMed
P.111 掲載の参考文献
1) 緒方 篤. 血沈, CRPとリウマチ性疾患. 七川歡次 (監修), リウマチ病セミナーX. 大阪, 永井書店, 1999: 197-203.
 
2) 安波礼子. 血沈正常のRAと異常のOA. 七川歡次 (監修), リウマチ病セミナーXII. 大阪, 永井書店, 2001: 175-181.
 
3) Hayem G, Ballard-Doireau M, Meyer O. Facteurs pronostiques de la polyarthrite rhumatoide debutante. In; L'Actualite Rhumatologique 2003 (Eds: Kahn MF, et al). Paris, Elsevier, 2003: 40-53.
 
4) Syversen SW, Gaarder PI, Goll GL, et al: High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008; 67: 212-217.
 
5) Courvoisier N, Dougados M, Cantagrel A, et al. Prognostic factors of 10-year radiographic outcome in eraly rheumatoid arthritis: a prospective study. Arthritis Res Ther 2008; 10.
 
6) Radovits BJ, Fransen J, van Riel PL, et al. Influence of age and gender on the 28-joint Disease Activity Score (DAS-28) in rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1127-1137.
 
7) Costenbader KH, Chibnik LB, Schur PH. Discordance between erythrocyte sedimentation rate and C-reactive protein rneasurements: clinical significance. Clin Exp Rheumatol 2007: 25: 746-749.
 
8) de Man YA, Hazes JM, van de Geijn FE, et al. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 716-722.
PubMed
9) Nicolaisen C, Figenscchau Y, Nossent JC. Anemia in early rheumatoid arthritis is associatied with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol 2008; 35: 380-386.
PubMed

生物学的反応

P.120 掲載の参考文献
1) Wada Y, Nishikawa A, Okamoto N, et al. Structure of serum transfering in carbohydrate-deficient glycoprotein syndrome. Biochem Biophys Res Commun 1992; 189: 832-836.
 
2) Wada Y, Azadi P, Costello CE, et al. Comparison of the methods for profiling glycoprotein glycans-HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology 2007: 17: 411-422.
PubMed
3) Parekh RB, Dwek RA, Sutton BJ, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316: 452-457.
PubMed
4) Gindzienska-Sieskiewicz E, Klimiuk PA, Kisiel DG, et al. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. Clin Rheumatol 2007; 26: 685-690.
PubMed
5) Axford JS, Sumar N, Alavi A, et al. Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 1992; 89: 1021-1031.
PubMed
6) Rademacher TW, Williams P, Dwek RA. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci U S A 1994; 91: 6123-6127.
PubMed
7) Malhotra R, Wormald MR, Rudd PM, et al. Glycosylation changes of lgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995; 1: 237-243.
 
8) Aoyagi Y, Isemura M, Suzuki Y, et al. Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet 1985; 2: 1353-1354.
PubMed
9) Shields RL, Lai J, Keck R, et al. Lack of fucose on hurnan IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733-26740.
 
10) Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670-673.
PubMed
P.127 掲載の参考文献
1) Rouvier E, Luciani MF, Mattei MG, et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993: 150: 5445-5456.
 
2) Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3: 811-821.
PubMed
3) Aggarwal S, Gurney AL. IL-17: prototype member of a emerging cytokine family. J Leuco Biol 2002; 71: 1-8.
 
4) Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-476.
PubMed
5) Infante-Duarte C, Horton HF, Byrne MC, et al. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000; 165: 6107-6115.
 
6) Chabaud M, Lubbers E, Joosten L, et al. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001; 3: 168-177.
 
7) Lubberts E, Joosten LA, van de Loo FA, et al. Overexpression of IL-17 in the knee joint of cpllagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 2001; 51: 102-104.
 
8) Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by rheumatoid synovium. Arthritis Rheum l 999: 42: 963-970.
 
9) Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-2682.
 
10) Page G, Miossec P. Rank and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 2005; 52: 2307-2312.
PubMed
11) Nakae S, Mambu A, Sudo K, et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171: 6173-6177.
 
12) Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 recceptors. Cytokine Growth Factor Rev 2003: 14: 155-174.
 
13) Chang SH, Park H, Dong C. Act-1 adaptor protein is an immediate and essential signaling component of interleukin-17 recptor. J Biol Chem 2006; 281: 35603-35607.
 
14) Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989: 7: 145-173.
PubMed
15) Billiau A, Hermans H, Vandekerckhove F, et al. Enhanced of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 1988; 140: 1506-1510.
 
16) Ferber IA, Brocke S, Taylor-Edwards C, et al. Mice with a disrupted interferon-γgene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156: 5-7.
 
17) Jacob CO, Holoshitz J, Van der Meide P, et al. Heterogeneous effects of Interferon-γin adjuvant-induced arthritis. J Immunol 1989; 142: 1500-1505.
 
18) Nkajima H, Takamori H, Hiyama Y, et al. The effect of treatment with recombinant gamma-interferon on adjuvant-induced arthritis in rat. Agents Actions 1991; 34: 63-65.
 
19) Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is critical cytokine for autoimmune inflammation of the brain. Nature 2003: 421: 744-748.
PubMed
20) Harrington LE, Hatton RD, Mangan Pr, et al. Interleukin-17 producing CD4+effcetor T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
 
21) Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
 
22) Veldhoen M, Hocking RJ, Atkins CJ, et al. TGF beta in the context of an inflammatory cytokine milieu supports de novo differnetiation of IL-17 producing T cells. Immunity 2006; 24: 179-189.
 
23) Mangan PR, Harrington LE, O' Quinn DB, et al. Tranforming growth factor-beta induces development of the T (H) 17lineage. Nature 2006; 441: 231-234.
 
24) Ivanov II, Mckenzie BS, Zhou L, et al. The orphan nuclear receptor ROR gamma t directs the differnetiation program of proinflammatory IL-17+T helper cells. Cell 2006: 126: 1121-1133.
 
25) Happel KI, Dubin PJ, Zheng M, et al. Divergentroles of IL-23 and IL12 in host defence against Klebsiella pneuminiae. J Exp Med 2005: 761-769.
 
P.133 掲載の参考文献
1) Lynda F. Bonewald. Osteocytes, Osteoporosis, Third edition Vol1. Chapter 8, 2008: 169-183.
 
2) Parfitt AM. The cellular basis of bone turnover and bone loss: A rebuttal of the osteocytic resorption-bone flow theory. Clin Orthop Relat Res 1997; 236-247.
 
3) Bordier PJ, Miravet L, Ryckerwaert A, et al. Morphological and morphometrical characteristics of the mineralization front. A vitamin D regulated sequence of bone remodeling. In Bone Histomorphometry (PJ. Bordier, ed.). Paris, Armour Montagu, 1976: 335-354.
 
4) Nijweide PJ, van der Plas A, Scherft JP. Biochemical and histological studies on various bone cell preparation. Calcif Tissue Int 1981: 33, 529-540.
PubMed
5) Palumbo C. A three-dimensional ultrastructual atudy of osteoid-osteocytes in the tibia of chick embryos. Cell Tissue res 1986; 246: 125-131.
 
6) Owen M. Cell population kinetics of an osteogenic tissue. I. 1963. Clin Orthop Relat Res 1995; 3-7.
PubMed
7) Kato Y, Boskey A, Bonewald LF, et al. Establishment of an osteoid preosteocyte like cell MLO-A5 that spontaneously mineralizes in culture. J Bone Miner Res 2001; 16: 1622-1633.
PubMed
8) Mikuni-Takagaki Y, Kakai Y, Saito S, et al. Matrix mineralization and the differentiation of osteocyte-like cells in culture. J Bone Miner Res 1995: 10: 231-242.
PubMed
9) Boskey A. Matrix proteins and mineralization: An overview. Connect Tissue Res 1996; 35: 357-363,
PubMed
10) Hunter GK, Hauschka PV, Poole AR, et al. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 1996; 317 (Pt 1): 59-64.
 
11) Strom TM, Francis F, Meitinger T, et al. Pex gene deletions in Gy and HYP mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet 1997: 6: 165-171.
PubMed
12) Blair HJ, Gormally E, Uwechue IC, et al. Mouse mutants carrying deletions that remove the genes mutated in Coffin-Lowry syndrome and lactic acidosis. Hum Mol Genet 1998; 7: 549-555.
PubMed
13) Winkler DG, Sutherland MK, Latham. JA, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267-6276.
PubMed
14) Gowen LC, Petersen DN, Brown TA, et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 2003; 278: 1998-2007,
PubMed
15) Wetterwald A, Hoffstetter W, Atkinson M, et al. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 1996; 18: 125-132.
PubMed
16) Schulze E, Witt M, Kasper M, et al. Immunohistochemical investigations on the differentiation marker protein E11 in rat calvaria, calvaria cell culture and the osteoblastic cell line ROS17/2.8. Histochem Cell Biol 1999; 111: 61-69.
 
17) Tenorio D, Cruchley A, Hughes FL. Immunocytochemical investigation of rat cementblast phenotype. J Periodontal Res 1993: 28: 411-419.
 
18) Westbroek I, De Rooij KE, Nijweide PJ. Osteocyte specific monoclonal antibody MAb OB7.3 is directed against PHEX protein. J Bone Miner Res 2002; 17: 845-853.
 
19) Ruchon AF, Tenenhouse AF, Boileau G, et al. Developmental expression and tissue distribution of PHEX protein: Effect of the HYP mutation and relationship to bone markers. J Bone Miner Res 2000; 15: 1440-1450.
 
20) Francis F, Henning S, Meitinger T. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995; 11: 130-136.
 
21) Feng JQ. DMP-1 deficient mice develop dwarfism, chondrodysplasia and disorganized bone re-modeling and mineralization during postnatal development. Vol. Abstract, American Society for Bone and Mineral Research, 2002.
 
22) Toyosawa S, Shintani S, Komori T, et al. Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. J Bone Miner Res 2001: 16: 2017-2026.
 
23) Feng JQ. Loss of Dmp1/DMP1 causes defects in skeletal mineralization and in phosphate handling: Potential role of the osteocyte in mineral metabolism. Submitted (2006).
 
24) He G, George A. Dentin matrix protein 1 immobilized on type I collagen fibrils facilitates apatite deposition in vitro. J Biol Chem 2004; 279: 11649-11656.
PubMed
25) Feng J, Ward LM, White KE, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38: 1310-1315.
PubMed
26) Rowe PS, de Zoysa Pa, Oudet CL, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000; 67: 54-68.
PubMed
27) Petersen DN, Tkalcevic GT, Mansolf AL, et al. Identification of osteoblast/osteocyte factor 45 (OF45), a bone specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts andosteocytes. J Biol Chem 2000; 275: 36172-36180.
PubMed
28) Igarashi M, Kamiya N, Ito M, et al. In situ localization and in vitro expression of osteoblast/osteocyte factor 45 mRNA during bone cell differentiation. Histochem J 2002: 34: 255-263.
 
29) Bresler D, Bruder J, Mohnike K, et al. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): Implications for phosphaturia and rickets. J Endocrinol 2004; 183: R1-9.
 
30) Rowe PS, Garrett IR, Gutierrez GE, et al. Surface Plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEP-ASARM motif: A model for impaired mineralization in X-linked rickets (HYP). Bone 2005; 36: 33-46.
 
31) Rowe PS, Kumagai Y, Mundy GR, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004: 34: 303-319.
PubMed
32) Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 2003; 44 (Suppl 1): 33-40.
 
33) Poole KE, van Bezooijen RL, Reeve J, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J, 19, 1842-1844, 2005
 
34) Balemans W, Ebeling M, van Hul W, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001: 10: 537-543.
 
35) van Bezooijen RL, Roelen BA, Lowik CW, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004; 199: 805-814.
 
36) Bellido T, Ali AA, Jilka RL, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: Anovel mechanism for hormonal control of osteoblastgenesis. Endocrinology 2005; 146: 4577-4583.
 
37) Burr DB, Robing AG, Turner CH. Effects of biomechanical stress on bones in animals. Bone 2002; 30: 781-786.
 
38) Enrlich PJ, Noble BS, Lanvon LE, et al. The effect of in vivo mechanical loading on estrogen receptor alpha expression in rat ulnar osteocytes. J Bone Miner Res 2002; 17: 1646-1655.
 
39) Lanyon LE Osteocytes, strain detection, bone modeling and remodeling. Calcif Tissue Int 1993; 53: S102-106, discussion S106-107.
 
40) Hirao M, Hashimoto J, Yamasaki N, et al. Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J Bone Miner Metab 2007; 25: 266-276.
PubMed
P.141 掲載の参考文献
1) Lipsky PE, van der Heijde DM, St Clair EW, et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
 
2) Klareskog L, van der Heijde D, de Jager JP, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-681.
PubMed
3) Arron JR, Choi Y. Bone versus immune system. Nature 2000; 408: 535-536.
PubMed
4) Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 259-269.
PubMed
5) Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-1488.
PubMed
6) Kim N, Kadono Y, Takami M, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005; 202: 589-595.
 
7) Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516-518.
PubMed
8) Zwerina J, Hayer S, Tohidast-Akrad M, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004: 50: 277-290.
PubMed
9) Zwerina J, Redlich K, Polzer K, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007; 104: 11742-11747.
PubMed
10) Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-320.
PubMed
11) Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998: 41: 2196-2204.
PubMed
12) Catrina AI, af Klint E, Ernestam S, et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006; 54: 76-81.
PubMed
13) Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309.
PubMed
14) Romas E, Sims NA, Hards DK, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002; 161: 1419-1427.
PubMed
15) Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 156-163.
PubMed
16) Glinka A, Wu W, Delius H, et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998; 391: 357-362.
PubMed
17) Bafico A, Liu G, Yaniv A, et al. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001; 3: 683-686.
PubMed
18) Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8: 751-764,
PubMed

治療と副作用

P.150 掲載の参考文献
1) Kremer JM, Henrry KG, Larry W, et al. Effect of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. a randomized trial. Ann Intern Med 2006; 144: 865-876.
 
2) Genovese MC, Becker JC, Michale S, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alfha inhibition. N Engl J Med 2005; 353: 1114-1123.
 
3) Bigbee CL, Gonchoroff DG, Vratsanos G, et al. treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 2007; 56: 2557-2565.
 
P.158 掲載の参考文献
1) リウマチ白書2005年, 日本リウマチ友の会.
 
2) 志水正敏. リウマチ患者への医療以外の援助. リウマチ病セミナーXV (七川歡次監修). 2004, p224-228, 大阪, 永井書店.
 
3) Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart Failure in Rheumatoid Arthritis:a population-based study over 46 years. Arthritis Rheum 2005;52:412-420.
PubMed
4) 志水正敏. RAと心血管イベント. リウマチ病セミナーXVIII (七川歡次監修). 2007, p1-7, 大阪, 永井書店.
 
5) 塩沢俊一. 膠原病学 改定3版. 東京, 丸善株式会社, 2008:421.
 
6) Mayou R, Farmer A. ABC of psychological medicine:Functional somatic symptoms and syndromes. BMJ 2002;325:265-268.
PubMed
7) Barsky AJ, Borus JF. Functional Somatic Syndromes. Ann Intern Med 1999:130:910-921.
PubMed
8) Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes:one or many? Lancet 1999;354:936-939.
PubMed
9) Bao G, Guilleminault C. Upper airway resistance syndrome:one decade later. Curr Opin Pulm Med 2004;10:461-467.
PubMed
10) 志水正敏. 上気道抵抗症候群. リウマチ病セミナーXVII (七川歡次監修). 2006, p76-82, 大阪, 永井書店.
 
11) 渡辺恭良. 疲労の分子脳神経メカニズム. 日本臨牀 2007:65:972-974.
Medical*Online
12) 熊ノ郷卓之, 足立浩祥, 杉田義郎. III. 慢性疲労症候群の臨床的特徴 2. 睡眠障害. 日本臨牀 2007; 65:1017-1022.
 
P.166 掲載の参考文献
1) Dinasrello CA. Interleukin-1, interleukin-1 receptors andinterleukin-1 receptor antagonist. Intern Rev Immunol 1998; 16: 457-499.
 
2) Arend WP, Malyak M, Guthridge CJ. Interlekin-1 receptor antagonist: Role in biology. Annu Rev Immunol 1998: 16: 27-55.
 
3) Dayer JM. Evidence for the biological modulation of IL-1 activity: The role of IL-1Ra Clin Exp Rheumatol 2002: 20 (Supple 27); S14-20,
 
4) 岩倉洋一郎. インターロイキン-1. 日本臨牀2005; 63増刊号: 153-157.
 
5) Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13: 323-340.
PubMed
6) Bresnihan B. Cytokine neutralizers: IL-1 inhibitors IN Rheumatology, 4th ed (Hochberg MC, Silman AJ, Smolen JS, eds), 2007, pp495-500, Mosby.
 
7) Dayer LM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2003; 42 (Suppl 2): ii3-ii10.
 
8) Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis 2000; 59 (Suppl I): i60-i64.
 
9) Burger D, Dayer JM, Palmer G, et al. Is IL-1 a good therapeutic target in the treatment of arthritis?Best Pract Res Clin Rheumatol 2006; 20: 879-896.
PubMed
10) Arend WP, Malyak M, Smith MF, et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994: 153; 4766-4774.
PubMed
11) Ludwiczek O, Vannier E, Borggraefe I, et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004; 138: 323-329.
PubMed
12) Arend WP, Welgus HG, Thompson RC, et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990: 85: 1694-1697.
PubMed
13) Hirsch E, Irikura VM, Paul SM, et al. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci USA 1996; 193: 11008-11013.
 
14) Firestein GS, Boyle DL, Yu C, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 37: 644-652, 1994.
PubMed
15) Waugh J, Perry CM Anakinra: a review of its use in the management of rheumatoid arthritis. Bio Drugs 2005: 19: 189-202.
 
16) Kary S, Burmester GR. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. lnt J Clin Pract 2003; 57: 231-234.
 
17) http://www.pmprb-cepmb.gc.ca/english/home.asp?x=1
 
18) Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-2204.
PubMed
19) Bresnihan B, Newmark R, Robbins S, et al. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 2004; 31: 1103-1111.
 
20) Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomized, placebo-controlled trial of anakinra (Kineret), arecombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63: 1062-1068.
PubMed
21) Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006-1012.
PubMed
22) Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007; 46: 1140-1147.
PubMed
23) Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006; 8: R174.
 
24) den Broeder AA, de Jong E, Franssen MJ, et al. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006; 65: 760-762.
PubMed
25) Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-1419.
PubMed
26) Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-624.
PubMed
27) Cohen SB, Rubbert A.: Bringing the clinical experience with anakinra to the patient. Rheumatology (Oxford) 2003: 42 (Suppl 2): ii36-ii40.
 
28) Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006; 65 (Suppl 3): iii2-iii15.
 
P.174 掲載の参考文献
1) 遠藤 拓, 赤木家康, 井上正生ら: 足趾変形したリウマチ足対応の靴の開発, 靴の医学2006; 20: 31-35.
 
2) 桃原茂樹, 宇佐見則夫, 香取利昭ら: 関節リウマチ患者における靴作製の留意点と工夫, 靴の医学2005; 19: 95-99.
 
3) 石塚忠雄: 新しい足と靴の医学. 東京, 金原出版株式会社, 1992: 173-176.
 
4) 田中尚喜, 伊藤晴夫: 腰痛・下肢痛のための靴選びガイド. 東京, 日本医事新報社, 2004: 64-65.
 
5) レネ・バウムガルトナー, ハルトム・シュティヌス, 赤木家康: 足と靴-その整形外科的処置法【改訂版】. フスウントシュー インスティテュート, 2002: 124-128.
 
P.180 掲載の参考文献
1) Hench PS. The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone. In: Nobel lectures, physiology or medicine 1942-1962. Amsterdam, Elsevier, 1964: 312-341.
 
2) Ward LE, Polley HF, Power MH, et al. Prednisone in rheumatoid arthritis: metabolic and clinical effects. Ann Rheum Dis 1958; 17: 145-159.
PubMed
3) Meyers FH, Jawetz E, Goldfien A. The adrenocortical steroids. In: Meyers FH, Jawetz E, Goldfien A editors. Review of medical pharmacology 7th edition. California, Lange Medical Publications, 1980: 353-368.
 
4) Conn HO, Blitzer BL: Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976; 294: 473-479.
PubMed
5) Tomlinson JW, Draper N, Mackie J, et al. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002; 87: 57-62.
 
6) 笠山宗正. ステロイド療法の現在と未来. 七川歡次 (監修). リウマチ病セミナーXV. 大阪, 永井書店, 2004: 211-218.
 
7) Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoid that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997; 11: 1245-1255.
PubMed
8) Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in Vitro separation of transrepression from transactivation activity. J Immunol 2001; 166: 1975-1982.
PubMed
9) Chivers JE, Gong W, King EM, et al. Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol 2006; 70: 2084-2095.
 
10) Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol. 2003; 17: 860-869.
 
11) Rosen J, Miner JN. The search for safer glucocorticoid receptor ligands. Endocr Rev. 2005; 26: 452-464.
PubMed
12) Wallberg-Jonsson S, Ohman ML, Dahlquist SR, et al. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997: 24: 445-451.
 
13) Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
PubMed
14) Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 1999; 340: 115-126.
 
15) Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003: 349: 2399-2406.
PubMed
16) Xu X, Otsuki M, Saito H, et al: PPAR α and GR differentially down-regulate the expression of nuclear factor-κ B-responsive genes in vascular endothelial cells. Endocrinology 2001; 142: 3332-3339.
 
17) Limbourg FP, Huang Z, Plumier JC, et al. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest 2002; 110: 1729-1738.
PubMed
18) 和泉真紀, 森田真也, 大月道夫ら: 吸入ステロイド薬の抗動脈硬化作用. 日本内分泌学会雑誌2007; 83: 119.
 
P.191 掲載の参考文献
1) 天谷忠弘, 横田智広. 新抗リウマチ薬タクロリムス (プログラフ) の基礎的・臨床的特徴. 中部リウマチ 2005; 36: 94-106.
 
2) Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/NFAT signaling regulates pancreatic β-cell growth and function. Nature 2006; 443: 345-349.
 
3) Tsujimura S, Saito K, Nawata M, et al. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 2007: 67: 380-388.
PubMed
4) Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006; 54: 3095-3103.
PubMed
5) Furst DE, Saag K, Fleischmenn MR, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2002; 46: 2020-2028.
 
6) Yocum DE, Furst DE, Kaine JL, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 3328-3337.
PubMed
7) Yocum DE, Furst DE, Bensen WG, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology 2004; 43: 992-999.
PubMed
8) Kremer JM, Habros, JS, Kolba KS, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 2003; 48: 2763-2768.
PubMed
9) Kondo H, Abe T, Hashimoto H, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004; 31: 243-251.
PubMed
10) Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 334-339.
PubMed
11) Anile M, Venuta F, Diso D, et al. Malignancies following lung transplantation. Transplant Proc 2007; 39: 1983-1984.
PubMed
12) Takahashi K, Motohashi H, Yonezawa A, et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother 2004; 38: 791-794.
PubMed
P.204 掲載の参考文献
1) 中井吉英, 美根和典, 島田 章ら. 慢性腹痛の心身医学的診断. 心身医1982; 22: 305-313.
 
2) Nakai Y, Fukunaga M Takebayashi N et al. Jpn J Psychosom Med 1993; 33: 569-577.
 
3) 中井吉英. 慢性疼痛とはなにか. 日本医事新報1996; 3772: 7-12.
 
4) 三木健司, 春日慎一, 赤堀脩. CRPS type II (カウザルギー) に対する薬物治療. 日手会誌2006; 23: 5: 587-590.
 
5) Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia Mayo. Clin Proc 1999: 74: 385-398.
PubMed
6) Amor B, Dougados M, Mijiyawa M. [Article in French][Criteria of the classification of spondylarthropathies]Rev Rhum Mal 0steoartic 1990; 57: 85-89.
PubMed
7) 三木健司, 行岡正雄. 線維筋痛症: 山下敏彦 (編). 運動器の痛み診療ハンドブック. 東京, 南江堂, 2007: 255-265.
 
8) Yunus M, Masi AT, Calabro JJ, et al. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981; 11: 151-171.
PubMed
9) 牛田享宏. 神経因性疾痛患者における脳活動変化. Functional MRIを用いて. 日本臓器製薬作成資料, 2005 9月.
 
10) 辻 陽雄. 腰痛患者のマネジメント-腰痛の病理と治療ケアの新動向. 日本臓器製薬作成資料, 2005 1月.
 
11) 井上和臣. 心のつぶやきあなたを変える. 認知療法自習マニュアル. 東京, 星和書店, 1997: 13-14.
 
12) 井上和臣. 心のつぶやきあなたを変える. 認知療法自習マニュアル. 東京, 星和書店, 1997: 129-133.
 
13) Schweizer A. On the edge of the primeval forest; and, more from the primeval forest, New York, Macmillan, 1931: 62.
 
P.212 掲載の参考文献
1) Falconer MA, McGeorge M, Begg AC. Observations on the cause and mechanism of symptom-production in sciatica and low-back pain. J Neurol Neurosurg Psychiatry 1948; 11: 13-26.
PubMed
2) Wiberg G. Back pain in relation to the nerve supply of the intervertebral disc. Acta Orthop Scand 1950; 19: 211-221.
 
3) Kuslich SD, Ulstrom CL, Michael CJ. The tissue origin of low back pain and sciatica: A report of pain response to tissue stimulation during operations on the lumbar spine using local anesthesia. Orthop Clin North Am 1991; 22: 181-187.
PubMed
4) Smyth MJ, Wright V. Sciatica and the intervertebral disc. An experimental study. J Bone Joint Surg [Am] 1958; 40: 1401-1418.
PubMed
5) Saunders HD. Use of spinal traction in the treatment of neck and back conditions. Clin Orthop 1983; 179: 31-38.
PubMed
6) Larsson U, Choeler U, Lindstroem A, et al. Auto-traction for treatment of lumbago-sciatica. Acta Orthop Scand 1980; 51: 791-798.
 
7) Ljunggren AE, Weber H, Larsen S. Autotraction versus manual traction in patients with prolapsed lumbar intervertebral discs. Scand J Rehab Med 1984; 16: 117-124.
 
8) Tesio L, Merlo A. Autotraction versus passive traction: An open controlled study in lumbar discherniation. Arch Phys Med Rehabil 1993; 74: 871-876.
 
9) Liunggren AE, Walker L, Weber H, et al. Manual traction versus isometric exercises in patients with herniated intervertebral lumbar discs. Physiotherapy Theory & Practice 1992; 8: 207-213.
 
10) Colachis SC Jr, Strohm BR. Effects of intermittent traction on separation of lumbar vertebrae. Arch Phys Med Rehabil 1969; 50: 251-258.
PubMed
11) Andersson GBJ, Schultz AB, Nachemson AL. Intervertebral disc pressures during traction. Scand J Rehabil Med 1984; 16: 88-91.
 
12) Ramos G, Martin W. Effects of vertebral axial decompression on intradiscal pressure. J Neurosurg 1994; 81: 350-353.
PubMed
13) Onel D, Tuzlaci M, Sari H, et al. Computed tomographic investigation of the effect of traction on lumbar disc herniations. Spine 1989; 14: 82-90.
PubMed
14) Mathews JA. Dynamic discography: A study of lumbar traction. Ann Phys Med 1968; 9: 275-279.
PubMed
15) Gillstroem P, Ericson K, Hindmarsh T. Autotraction in lumbar disc herniation. A myelographic study before and after treatment. Arch Orthop Trauma Surg 1985; 104: 207-210.
 
16) Ljunggren AE, Eldevik OP. Autotraction in lumbar disc herniation with CT examination before and after treatment, showing no change in appearance of the herniated tissue. J Oslo City Hosp 1986; 36: 87-91.
PubMed
17) Lindstroem A, Zachrisson M. Physical theraphy on low back pain and sciatica. An attempt at evaluation. Scand J Rehab Med 1970; 2: 37-42.
 
18) Mathews JA, Hickling J. Lumbar traction: A double-blind controlled study for sciatica. Rheum Rehabil 1975; 14: 222-225.
 
19) Coxhead CE, Inskip H, Meade TW, et al. Multicenter trial of physiotherapy in the management of sciatic symptoms. Lancet 1981; May 16: 1065-1068.
 
20) Mathews W, Morkel M, Mathews J. Manipulation and traction for lumbago and sciatica: Physio-therapeutic techniques used in two controlled trials. Physioth Pract 1988; 4: 201-206.
 
21) Sweetman BJ, Heinrich I, Anderson JAD. A randomized controlled trial of exercises, short wave diathermy, and traction for low back pain, with evidence of diagnosis-related response to treatment. J Orthop Rheumatol 1993; 6: 159-166.
 
22) van der Heijden GLMG, Beurskens AJHM, Dirx MJM, et al. Efficacy of lumbar traction: A randomised clinical trial. Physiotherapy 1995; 81: 29-35.
 
23) Beurskens AJ, de Vet HC, Koeke AJ, et al. Efficacy of traction for nonspecific low back pain, 12-week and 6-month results of a randomized clinical trial. Spine 1997; 22: 2756-2762.
 
24) Werners R, Pynsent PB, Bulstrode CJK. Randomized trial comparing interferential therapy with motorized lumbar traction and massage in the management of low back pain in a primary care setting. Spine 1999; 24: 1579-1584.
 
25) Borman P, Keskin D, Bodur H. The efficacy of lumbar traction in the management of patients with low back pain. Rheumatol Int 2003; 23: 82-86.
PubMed
26) Sherry E, Kitchener P, Smart R. A prospective randomized controlled study of VAX-D and TENS for the treatment of chronic low back pain. Neurol Research 2001; 23: 780-784.
 
27) Larsson U, Choeler U, Lidstroem A. Auto-traction for treatment of lumbago-sciatica. A multicenter controlled investigation. Acta Orthop Scand 1980; 51: 791-798.
 
28) Ljunggren AE, Weber H, Larsen S. Autotraction versus manual traction in patients with prolapsed lumbar intervertebral discs. Scand J Rehab Med 1984; 16: 117-124.
 
29) Ljunggren AE, Walker L, Weber H, et al. Manual traction versus isometric exercises in patients with herniated intervertebral lumbar discs. Physioth Pract 1992; 8: 207-213.
 
30) van Tulder MW, Assendelft WJ, Koes BW, et al. Method guidlines for systemic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine 1997; 22: 2323-2330.
 
31) van Tulder M, Furlan A, Bombardier C, et al. Updated method guidelines for systemic reviews in the Cochrane Collaboration Back Review Group. Spine 2003; 28: 1290-1299.
 
32) Clarke J, van Tulder M, Blomberg S, et al. Traction for low back pain with or without sciatica: An updated systematic review within the framework of the Cochrane Collaboration. Spine 2006; 31: 1591-1599.
 
P.222 掲載の参考文献
1) 医薬品・治療研究会. TIP 「正しい治療と薬の情報」誌: http://www.tip.gr.jp/
 
2) NPO法人医薬ビジランスセンター, 『薬のチェックは命のチェック』http://npojip.org
 
3) Rathway NJ ら編集. The MERCK MANUAL 16th ed. 日本語訳: 福島雅典総編集, 日本語版, 第1版, メディカル・ブックサービス, 1994年.
 
4) Choy EH, et al; Intramuscular Methylprednisolone Study Group. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005 64: 1288-1293.
 
5) Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: JAMA 2006; 295: 2275-2285.
PubMed
6) Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65: 379-384.
PubMed
7) Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697-1702.
PubMed
8) Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-1593.
PubMed
9) ワイス株式会社, エンブレル皮下注用25mg [エタネルセプトに関する資料] http://www.info.pmda.go.jp/shinyaku/g050102/index.html?submit=%C9%BD%BC%A8
 
10) 島津恒敏浜六郎. プロトピック軟膏 (タクロリムス水和物) は危険TIP「正しい治療と薬の情報」 2003; 18: 65-73.
 
11) 浜 六郎. 小児用プロトピック (タクロリムス水和物) 軟膏-濃度・発癌関係が明瞭 (動物実験). TIP 「正しい治療と薬の情報」 2003; 18: 86-90.
 
12) 医薬ビジランスセンター (薬のチェック), 医薬品・治療研究会. プロトピック (タクロリムス水和物) 0.03%軟膏の不承認を求める要望書. TIP 「正しい治療と薬の情報」 2003; 18: 90-91.
 
13) FDA, Pediatric Advisory Cornmittee. Feb 1 5, 2005 Letter by Dr. Rokuro Hama. MD http://www.fda.gov/ohrms/dockets/AC/05/slides/2005-4089s2.htm
 
14) 浜 六郎. シメチジン (タガメット) 注と血液障害. TIP 「正しい治療と薬の情報」 1986: 71-73.
 
15) 浜 六郎. ヒスタミンH2受容体拮抗薬 (H2ブロッカー) による血液毒性と感染症: 重症肝障害, 腎障害では特に注意を. TIP 「正しい治療と薬の情報」 1996: 37-39.
 
16) オーストラリア治療ガイドライン委員会著. 医薬品・治療研究会・医薬ビジランス研究所翻訳, 消化器疾患治療ガイドライン. 医薬ビジランスセンター発行, 1999.
 
17) 浜 六郎. Drug Information (30), ステロイド離脱症状としての偽リウマチ膠原病症候群. medicina 1998; 1859-1863.
 

手術

P.238 掲載の参考文献
1) 徳永大作, 北条達也, 山崎隆仁ら. 関節リウマチ前足部変形に対する関節形成術の成績. 日本リウマチ関節外科学会誌2005: 24: 279.
 
2) 黒坂 望, 三ツ木直人, 斎藤知行. 関節リウマチによる足部障害への対応. 前足部変形, 切除関節形成術-Lelievre 手術による関節リウマチ前足部変形の治療成績. 関節外科2005; 24: 145-154.
 
3) 松本卓巳, 門野夕峰, 山本 基ら. 関節リウマチ前足部変形に対する切除関節形成術の成績. 第51回日本リウマチ学会, 第16回国際リウマチシンポジウム抄録集2007: 364.
 
4) 藤原一夫, 西田幸一郎, 北村亜以ら. 関節リウマチ患者前足部変形に対する足趾形成術の長期成績. 第51回日本リウマチ学会, 第16回国際リウマチシンポジウム抄録集2007: 364.
 
5) 服部宏行, 山本謙吾, 野原亜也斗ら. RA前足部障害に対する切除関節形成術の術後評価. 第50回リウマチ学会, 第15回国際シンポジウム抄録集2006: 192.
 
6) 辻 王成, 堺 慎, 大川 匡ら. 関節リウマチの前足部変形に対する切除関節形成術の術後成績. 北海道整形災害外科学雑誌2005; 46: 62-63.
 
7) 大脇 肇, 高樋康一郎, 富士武史. RAに対する第1-5中足骨骨切り術 (MTP関節温存術式) の短期成績. 日本リウマチ関節外科学会誌2005; 24: 279.
 
8) 磯本慎二, 田中康仁, 成川功一ら. RAの前足部変形に対する切除形成術-母趾MTP関節に対する術式の相違による成績の比較. 日本リウマチ関節外科学会誌2005: 24: 280,
 
9) 史賢林, 村田賢治, 大脇 肇ら. 関節リウマチ外反母趾に対するopen wedge osteotomyによる第1中足骨矯正骨切り術を併用した, 第1MTP関節のSwanson inplant による人工関節置換術の術後成績. 第50回日本リウマチ学会, 第15回国際シンポジウム抄録集2006: 192.
 
10) Nagashima M, Kato K Miyamoto Y, et al. A modified Hohmann method for hallux valgus and telescoping osteutomy for lesser toe deformities in patients with rheumatoid arthritis. Clin Rheumat 2007; 26: 748-752.
 
11) Kadambande S, Debnath U, Khurana A, et al. Rheumatoid for foot reconstruction: 1st metatarsophalangeal fusion and excision arthroplasty of lesser metatarsal heads. Acta Orthop Belg 2007; 73: 88-95.
PubMed
12) Grondal L, Brostrom E, Wretenberg F, et al. Arthrodesis versus Mayo resection: the management of the first metatarsuphalangeal joint in reconstruction of the rheumatoid forefoot. J. Bone and Joint Surg Br 2006; 88: 914-919.
 
13) Thomas S, Kinninmonth AWGA, Kumar CS. Long-term results of the modified Hoffman proceders in the rheumatoid forefoot. Surgical technique. J Bone Joint Surg Am 2006; 88 (suppl. 1): 145-157.
 

書評

最近チェックした商品履歴

Loading...